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INTRODUCTION 
 
 
 The siddha system of medicine is our heritage knowledge on 
health care, a treasure of indigenous medicine. Siddha system of 
medicine is being practiced from the birth of our Tamil language. It 
has its own lot of numerous specialities & incomparable to other 
systems of medicine. Inspite of the great & spectacular advances 
in modern medical sciences in the war against diseases & 
disorders the mankinds rely on traditional system of medicine and 
seeks the usage of medicinal plants & their products for curing 
ailments. 
 
  Herbal medicine believes that the ailments results only in 
case of internal uncleanliness and tries to root them. Siddha 
system of medicine excels in the manner in which it deals with the 
human body and its diseases. It tends to lay emphasis in 
prevention of diseases rather than curing it. It also encourages one 
to maintain his health by paying attention to balance one’s life 
through diet and lifestyle. In enables one to understand how to 
create balance of body, mind and soul according to one’s own 
individual constitution and how to make life style changes to regain 
the balance that they have lost in their physical living and maintain 
the vital force essential for leading successful life. 
 
 In siddha system of medicine the tridoshas namely, vatha, 
pitha and kapha are essential constituents of the living body which 
are responsible for regulating all the body functions. 
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      ‘caph;f;fhjhuk; caph;jhnjdTk; 
Kg;gphpthfp Kf;FzkZfp 
cliyAk; capiuAk; Nkhk;gpf;fhj;J 
 tUnkd; KJkiw tFf;Fe; JzpNg” 
 
In healthy persons, the tridoshas maintain proper functioning 
of all the organs and tissues depending upon individual needs. 
Siddha system of medicine lays great emphasis on early changes 
caused by disturbances of doshas in the whole body,  as a result 
of excessive turnover of these substances and it is at these stages 
that one can prevent the development of disease in a full fledged 
manner.  
 
Siddha system of medicine is also known for its simple 
principle. 
 
      ‘czNt kUe;J> kUe;Nj czT” 
           Which is also said by Hippocrates as  
        “Let thy food be medicine 
       And the medicine be thy food” 
 
The two words food & medicine denote the same meaning. 
In health it is taken as food and taken as medicine in ill- health 
where its dosage only differs. 
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The formation of six tastes from five elements 
(panchabuthas) & their role in siddha medicinal formulations & 
principles are well known.  
 
It is of paramount importance to acquire international 
acceptance of our own siddha system of medicine is of utmost 
importance & demanding in this current situation. This brings the 
need for scientific investigation of herbs used in siddha system 
using the modern parameters & methods of study like 
phytochemistry, biochemical analysis, pharmacological study & 
clinical trial. These all steps, one or the other will give us new 
insights and understanding into the rationale for the use of these 
herbs.  
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AIM 
 
 The drug Ilavangathi choornam chosen from siddha literature 
is to be studied in 50 Iya Eraippu patients by open clinical trial for 
the duration of one month. The results and observations have to 
be documented by means of standard statistical calculations. By 
this the efficacy of a siddha drug which in unrevealed, yet is to be 
documented. 
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OBJECTIVES 
1. The Primary objective of this study is to do an open clinical 
trial on Iya Eraippu noi affected individuals with the trial drug. 
 Drug- Ilavangathi choornam 4 g t.d.s. with honey, after food. 
 Taken from the literature Sigicharathnadeepam. 
 
2. To make a detailed study of various siddha literatures like 
Yugi vaidya chinthamani 800, Agasthiyar 2000, Theraiyar 
Vagadam, Jeevaratchamirtham, etc. 
 
3. To analyse the correlation of etiology, classification, signs & 
symptoms of Iya Eraippu noi in siddha aspect with Bronchial 
asthma in modern aspects.  
 
4. To have an idea about the incidence of the disease with 
regard to age, sex, socio-economic status, occupation, family 
history and paruvakalam. 
 
5. To study how the disease Iya Eraippu Noi alters the normal 
condition under the headings mukkutram, poripulangal, 
seven udalthathukkal, Neerkuri & Neikuri and Envagai thervu  
especially, Naadi Nadai. 
 
6. To make a detailed clinical evaluation of the disease by a 
careful examination on etiology, signs & symptoms, 
complaints, past history of patients to allergic disease, 
sinusitis, or occupation, treatment and prognosis during the 
course of the Iya Erappu noi. 
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7. To utilize the possible modern evaluatory equipment and lab 
investigation to conduct the clinical trial.  
 
8. To evaluate the biochemical, phytochemical & 
pharmacological studies of trial drug to establish the efficacy.  
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REVIEW OF LITERATURES 
 
SIDDHA  
 
 The disease Bronchial asthma can be correlated in Siddha  
as Iya Eraippu or Mandara Kasam. Here, we can discuss on 
various author’s view on Eraippu noi, beginning from their etiology, 
classification, prodormal signs & symptoms, diseased state, 
prognosis of disease, etc. 
 
Etiology:  
 
 According to Yugi vaidya chinthamani – 800, 
 
‘Ntfpd;w tjpfkhk; GifapdhYk; 
kPWfpd;w ghzj;jhy; kpFf;Fe;jhNd 
ghzj;jhy; gukhf;fpdp kpFf;ifahYk; 
ghu khkprq;fs; Grpf;ifahYk; 
jhzj;jhw; rQ;rhuk; jtph;f;ifahYk; 
rhpglh gjhh;j;jq;fs; Grpj;jjhYk; 
jPzj;jhw; GrpahkypUf;ifahYk; 
Nrapioahh; NkypigQ; rpijtjhYk; 
khzj;jhy; khJf;f kiltjhYk; 
kjj;jhYQ; RthrkJ kUTq;fhNz” 
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• Smoke and fumes  
• Excessive intake of cold & hot drinks 
• Due to disturbances in digestion 
• Excessive  intake of non- vegetarian food 
• Consumption of improperly cooked food  
• Not being generous 
• Excessive sexual indulgence  
 
According to siddhar Kaiyezhuthu pirathi,  
 
‘fhy ngUf;FzTg; nghUs; jz;zPh; khwy; 
fUjpUky; kpfy; the;jp Fsph;e;j fhw;W 
khy; nra;J ehs;NjhWk; tUe;Jk; fha;r;ry; 
ke;jd Kaph;epiyapy; mbfs; jhf;fy; 
VyrPjNgjp tplghz;L Giffs; 
,yfpa ney;yhjp kzpr; RizAl; nry;yy; 
Nky; topapy; rpythpD kpiug;ghk; NehA 
NkTnkd Kdpth;fs; tpsk;gpdNu” 
• Excessive intake  of food at inappropriate time 
• Change in drinking water 
• Cough 
• Vomiting 
• Cold air 
• Fever 
• Trauma to vital organs 
• Dysentery  
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• Anaemic due to toxic substances  
• Fumes and smoke  
• Pollens from grasses etc., any of the above are the  
     Causes which may induce asthma  
 
According to Jeevarakshamirtham  
 
• Excessive cough 
• Intake of substances which promotes vatham 
• Diarrhoea & vomiting 
• Anameic due to toxic substances  
• Exposure to cold climate & cold air 
• Trauma to vital organs. 
 
 The modern science gives atopic etiology for Bronchial 
asthma, which our siddhars have also defined as an important 
cause which was referred in Agasthiyar Guru Naadi Sasthiram. 
 
‘cw;wpLk; cyfj;NjhUf;F cWgy tpahjpnay;yhk;  
kw;wpLk; Fzq;fs; jd;id gfh;e;Jiu nra;a Ntz;by; 
xj;jpLk; rd;duhYk; clYapUsthYk; 
mj;jpkh kiyapy; thOk; khKdp tFj;jjhNk” 
 
So as the Thirumoolar says, 
 
‘Ngh; ,sik ,d;gk; gpzp%g;G rhf;fhL 
MWk; fUtpy; mikg;G” 
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Prodormal signs & symptoms  
 
A siddha maruthuva Kaiyezhuthu pirathi says, about the prodormal 
signs and symptoms as 
 
‘khh;gpy; tpyhtpuz;by; kw;WkpU nehpapy; Nrh;e;J 
typj;jy; jpzwy; m‡jhy; %r;R 
cg;gy; tapw;wpy; cUJNt Kw;Fwpahr; 
nra;A kpiug;G Neha;f;fpjidr; Nrh;” 
• Pain in the chest  
• Pain in the intercostal region 
• Dyspnoea 
• Distention of abdomen  
• Followed by asthmatic attack  
 
Theraiyar, says in his Theraiyar vagadam as follows 
 
‘te;jpLk; nts;Nshf;fhsk; thaJ jpj;jpg;ghFk; 
nehe;jpLk; gplhpkz;il ke;jKk; kpisg;gpNdhh;f;Fk; 
Ke;jNt jiyjh ndhe;J rhPu KfKq; Fj;Jk; 
fe;juj; njhz;il ehrp fufud;WlNd Jk;ky;” 
• Nausea 
• Sweet taste in the mouth 
• Pain in the occipital region 
• Indigestion  
• Headache  
• Pricking pain in the body, face 
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• Irritation in throat, nasal region 
• Sneezing 
• Sneezing is followed by dry cough  
 
In siddha maruthuvam, asthma is also compared to 
mandarkasam or kulir Erumal Noi. 
 
‘jhdhd J}aNjhh; ehrp jd;dpy; 
ryNeha;ePh; jhd; tpOe;J Jk;g Yz;lhk; 
khdhd khh;G neQ; rilj;J %r;R 
tYthfg; ghk;GNghy; rPw yhFk; 
fhdhd fz;lnkhU KfKq; fhJq;  
fhakJq; frpthfp tpah;it ahFk; 
Vdhd ,UknyhL Nfhiof; fk;ky; 
,iug;ghF ke;jhu fhrkhNk.” 
 
• Rhinitis  
• Sneezing  
• Constriction of chest like sensation 
• Breathing sound is like snake snarling 
• Sweating over face & body 
• Cough with little expectoration 
• Dyspnoea are the signs & symptoms of mandara kasam  
 
‘ke;jhu fhrk; kiokg;G khh;G neQ;R 
je;jhd kPis jdpailj;j Fj;jpUky; 
Jk;gy; typ ehrpePh; Rukpisg; ghrkjp  
nghk;kptU nkd;W Gfy;” 
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- Mandara Kasam occurs due to rain, dyspnoea followed by 
constriction of chest like sensation, non – productive cough, 
sneezing, rhinitis, sometimes fever. 
 
Classification: 
According to siddha maruthuram, Eraippu noi is classified as:- 
 
1. Vali Eraippu 
2. Iya Eraippu 
3. Iyavali Eraippu 
4. Mukutra Eraippu 
5. Mel Nokku Eraippu 
 
 Following are the signs & symptoms - 
 
1.  Vali Eraippu: 
 
 Consumption of food those are not easily digestible.  
 Wandering in hot sun. 
 Consuming tubers like potato. 
 
 All the condition above stated will cause vitiation of vali 
dosha & together with it, if the person is physically debilitated may 
result in difficulty in breathing in & out. 
 
• A sensation of vaccum in the chest. 
• This condition does not give much grief to the patient. 
• This condition can be easily curable.  
• This is also known as ‘soothira swasam’. 
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2. Iya Eraippu: 
 
• Consumption of food causing Kapha dosha. 
• Due to rain and cold air vitiated kapha reaches head 
results in nasal block, rhinitis followed by constriction of 
chest difficulty in inspiration and expiration.  
• If expectoration is possible with cough, the difficulty in 
breathing will get relieved. 
• Otherwise, the patient gets dyspnoeic, wheezing. 
• Patient is unable to lie down supine. 
• Sweating in forehead, discoloration of face, anxious look 
due to dyspnoeic state, cold peripheries, dryness of 
mouth, severe dyspnoea, unable to lie down supine.  
• These are the signs & symptoms characterstic of Iya 
eraippu or ‘Thamakka Swasam’. 
 
3. Iya Vali Eraippu: 
 
 In this diseased state, both Iyam & vali dosha together get 
deranged and results in following signs & symptoms- 
 
• Vali dosha gets deranged and along with Udanan, causes 
difficulty in inspiration & expiration. 
• Also causes constipation & oliguria, distention of abdomen.  
• Dryness of mouth, redness of eyes, sweating, state of 
delirium & giddiness.  
• This condition is called ‘vitchinna swasam’. 
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4. Mukutra Eraippu: 
 
 The tridoshas together gets deranged and alters the normal 
state of udanan, abanan, vyanan & samanan results in emaciation 
of seven udalthathukkal thus resulting in eraippu noi worsening the 
patient’s condition. 
 
• Before setting in wheezing attack causes severe dysponea 
and anxiety. 
• The act of expiration is compared to breathe out by a big 
cow. 
• Constriction of chest, syncope, constipation, Oliguria, 
distention of abdomen, myalgia, delirious state, sweating in 
forehead. 
• This condition is known as ‘Maha swasam’. 
 
5.  Melnokku Eraippu: 
 
 Above four types of Eraippu being refractory to treatment, 
leads to chronic state called ‘melnokku eraippu’. 
 
 This occur due to altered state of udanan causing difficulty in 
expiration, dyspnoea, protrusion of eyeball, dryness of mouth, 
unable to lie from supine, air hunger by opening his mouth. 
 
At this state immediate treatment should be given, otherwise 
patient face gets cyanosed, keeps his mouth open gasping for 
want of air, syncope & results in death.  
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In Jeevarakshamirtham, the disease is classified into 5 types 
 
1. Soothira Swasam 
2. Thamakka Swasam 
3. Vitchinna Swasam 
4. Maha  Swasam 
5. Oorthuva swasam 
 
Sarabendra vaidya muraigal classifies swasa noi as 7 types 
 
1. Maha swasam 
2. Oorthuva swasam 
3. Chinna swasam 
4. Thamaka Swasam 
5. Soothira swasam 
6. Pirantha maha swasam 
7. Santha maha swasam 
 
Vaidya sara sangraham classifies as 
 
1. Manthara Eraippu 
2. Swasa kasam 
3. Pachai udambi ledutha swasakasam 
 
According to Anubhava vaidya devaragasiyam the disease is 
classified as  
 
 
 
 16
1. Arpa Swasam 
2. Thamaraka swasam 
3. Vitchinna swasam 
4. Maha swasam 
5. Oorthurva swasam 
 
Agasthiyar 2000 says about Mandarkasam as       
 
‘ke;jhufhrk; te;jhy; thq;fpLQ; RthrNkyh 
apj;jhu nka;r;RuNk fhZkpisj;jpL kpUky; nkj;JQ; 
re;jhTlk;G jiyAlk;G jsutypf;F kpisg;ghFk; 
ape;jhJlk;G neQ;RKfk; gj;jptypf;Fk; gz;gpJNt” 
 
‘,f;fz kjNdnlhf;f tpUkY kpisg;Gz;lha; 
rpfnfd neQ;rpfl;br; rPwpL kpWfpg; gw;wp 
gf;fke; jhue; jd;dpy; gw;wpa fhrkhNk” 
 
• Dyspnoea 
• Fever 
• Cough 
• Myalgia, headache  
• Pain in the chest 
• Coughs, dyspnoea, constriction of chest are the symptoms 
follows before an asthmatic attack. 
 
 
He also specifically says about kapha mandara kasam as 
 
 
 17
 
‘Ja;aNjhh; ehrpjd;dpy; Jk;kY kpfTz;lhfp 
neha;A ePuha; tpOe;J neQ;R NehTl dPiothq;F 
ma;apd;ke; jhufhrj; jltpJjhNd ePNfs; 
nra;Akh Kdpth; nrhd;d FzkpJ njhpe;J nfhs;Ns” 
 
• Sneezing 
• Rhinitis  
• Constriction of chest 
• Cough, dyspnoea  
 
In Athmaratchamirtha vaidya sarasangiragam,signs & 
symptoms of mandara kasam is stated as follows 
 
• Itching sensation over face & ear 
• Sneezing, rhinitis 
• Cough, dyspnoea 
• Pain in the chest & intecostal region 
• These symptoms are aggravated during winter season  
• Flatulence, giddiness, etc., 
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MUKKUTRA VERUPADUGAL – SIDDHA PATHOLOGY 
 
 In Siddha system of medicine the manifestations of all 
diseases are the result of derangement of tridoshas – vatha, pitha 
and Kapha. 
 
Noi Naadal Noi muthal Naadal: 
 
‘njhz;ilnad;gpd; re;jpepwTk; Nrhw;Wg;ig ehrpjiy 
Xz;nlhba thkj; Jsgpj;jj; - njhz;zPh;r; 
Rug;gp apurjhJ Rj;jepzk; ehTk; 
jukhd itaj; jplk;” 
-kUj;Jt jdpg;ghly; 
From the above quotation,it is clear that the stomach is one 
among the sites of kapha. The function of kapha in gastro intestinal 
tract is to tolerate the thirst and appetite which results in anorexia 
and indigestion. It produces `amam’ in the stomach which in turn 
also vitiates kapha. Thus the vitiated kapha is responsible for the 
respiratory disorder.  
 
 This is also clearly understood by the following phrase. 
 
‘fgj;jpidad;wp fhr Rthrq; fhzhJ” 
- Njiuah; 
 
 Excess of kapha in the respiratory organ affects the 
melnokkukal and uyirkal, due to this air is unable to reach the 
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terminal point of respiration produces gasping and labored 
breathing.  
 
 Few authors say, Eraippu noi is caused by deranged vatha. 
It was admitted because the obstruction of air in the respiratory 
tract is abnormal. Excessive consumption of vatha promoting diet 
induces the pitha. This vitiated pitha produces more heat & this 
further reaches the head resulting in rhinitis, heaviness of head 
and neck & sneezing. This is indicated by the following quote- 
 
‘gpj;jk; kpFe;jhy; <is ,UkYk; ngyj;J epw;Fk; 
cw;wpLk; Iaehb Xq;fpNa Jbj;J epd;why; 
gw;wpLk; ,Uky; <is gjwpNa ,iug;Gz;lhfp 
nkj;jNt Nfhio tha; kpFjpg; gLk;” 
 
Naadi Nadai: 
 
‘Kg;gpzp kUtp KdpT nfhs; Fwpg;igj; jg;gh 
jwpAk; jd;ikAk; thj gpj;jitak; gphpitA  
kitjhk; Vwpapwq;fp ,ize;Jf; fye;Jkhwp 
khwptUk; nraw;ifahw; gpzp Neh;ikawpe;J 
ePl;L kUe;Nj rPhpajhnkdr; nrg;Gth; rpj;jNu” 
 
‘%d;wpnyhd; Wah;e;jij Kd;duwpe;J 
Ke;jpajid nahopj;jpL kUe;jpL 
jzpAk; Nehapd; je;jpukpJNt 
Ngzpf; fzpj;jpbd; gpwtha; gpd; Fzk;” 
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From the above quotes, Naadi examination is the best 
method to elucidate the patient’s condition to do appropriate 
treatment. Also the three humors vatha, pitha & kapha together 
from the Naadi & their variation from regular function results in 
diseased state. 
 
The various types of Naadi Nadai in the disease Iya Eraippu: 
 
 The Manifestations of Mandara kasam due to deranged Iya 
Naadi: 
 
As per siddha Maruthuvam, the primary cause of this 
disease is due to deranged kapha, which plugs the airways and 
results in difficulty in breathing. 
 
‘jhdKs;s Nrj;J ke;jhdpypfpy;  ntg;G 
rakPisapUky; ke;jhu fhrk; 
<dKWQ;re;jp tplNjNjhlk; tpf;fy; 
apUj;Nuhfq;fug;ghd; tpuz Njhlk; 
khdizaPh; #iy jpus; tpahjp tPf;fk; 
tUQ;rj;jp Rthrk; neQ;rilg;G J}f;fk; 
Vd KWq;fhkhiy ghz;L Nrhig 
VO Ruq;fs; gyJf;Fk; tpl Kz;lhNk” 
 
‘IaNk fjpj;j NghjwpaNt nghUky; fhZk; 
        ieAke;jhufhrk; esph; Fsph; tpf;fy; rj;jp> 
nra;Akh %h;r;rilg;G jPjW fhrNuhfk; 
njha;Akh kpidg;G fhrk; Njhd;W nkd;wud; nrhd;dhNu” 
 
g.rp. ehb 
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‘tplq;fpa ita Nkypiug; Ngw;wpLk; 
jlq;fpapUkpLe;jd; tpyh tpuz;Lk; NehFk; 
   
jpU%yh; 
‘cw;wpLk; Iaehb Xq;fpNa Jbj;J epd;why; 
gw;wpLk; <is gjwpNa ,iug;Gz;lhf;fp 
nkj;jNt Nfhio tha; kpFjpg;gLk;” 
 
m.F 
Iyapitha Thontha Naadi 
‘,lkhd Nrj;Jkj;jpy; gpj;jehb 
vOe;jZfpy; tplKlNd tPf;fKz;lhk; 
jplkhd Fsph; fha;r;ry; kQ;rs; NehTe; 
Njfj;jpYisr;rypisg; gpUky; the;jp 
tplkhd neQ;rilg;G Rthrk; tpf;fy; 
ntFRuKk; ehtwl;rp ghz;L Nuhfk; 
mlkhd Ftisuj;j kjprhue;jhd; 
mZfp ntFgy Neha;f;Fj; jlq;fz;lhNa” 
 
According to few siddhars school of throught, the primary cause of 
the disease is due to deranged vali dosha, as it affects the free flow 
of air through the airways for breathing.  
 
Mandara Kasam due to vatha Iya thodam: 
 
‘ghq;fhd thjj;jpy; Nrj;Jk ehbg;  
ghprpj;jhy; jpkph; NkT Kisr;ryhFk; 
jPq;fhd ,UkYld; re;ep Njhlk; 
Nrh;e;j tplk; ntb#iy apUj;Nuhfk; 
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thq;fhj <is ke;jhufhrk; 
 typAlNd GwtPr;RAs; tPr;R tPf;fk; 
Xq;fhZr;Ru KlNd Rthrfhrk; 
cz;lhFk; ntF Neha;f;F KWjpjhNd” 
 
Due to ushnam with deranged Iyam causes swasakasam as 
per sathaga Naadi 
 
‘fjpg;ghd Nrj;Jkj;jpYl;bzq; $by; 
fye;j FzQ;rakpUky; Rthrfhrk;” 
 
Vayu with deranged Kapha also  can cause swasakasam 
says sathaga Naadi 
 
‘njhe;jpj;j Nrj;Jkj;jpy; thA $bj; njhlh;e;j 
Fd;kk; neQ;rilg;G Rthrfhrk;” 
 
Seethalam with deranged Iyam causes swasam 
 
‘milthd Nrj;Jkj;jpy; rPjsk; gw;wpy; 
mZfpdhy; Rthrkilg;Gapisg;G %h;r;ir..” 
 
Dietary recommendations & restrictions for Kapha 
constitution & patients by siddhars-  
 
‘Ntis kzj;jf;fhsp nkd;rPij rf;uth;j;jp 
gPis triy Rf;F ngz;Rzq;fs; - Ntisapiy 
nre;jsph; fisf;fPiu nra;th; fgNjfh; epjk; 
te;jdp Azj;jhd; kfpo;e;J” 
g.F.rp 
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‘fj;jhp Nga;g;Gly; tiu apUghfy; gUq;fsh fz;lfhhp 
 Mj;jpf; fha;fSk; tUf;ifkh gaw;iw fiuahy;  gPh;f;fUk; gpQ;RNth; 
nkha;j;j #uzq; fjypj; jz;Lfisg; g+Kypq;fp KUf;fUk;Gk; 
mj;jp g+rpdpf; fhaUs;sp ts;spAq; fgj;Njhh;f; fhzkhNk” 
 
g.F.rp.  
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PHYSIOLOGICAL ANATOMY   
 
 The organs of respiration consist of the respiratory passages 
and the lungs. The respiratory passage consists of the nasal 
cavities, pharynx, larynx, trachea, bronchi & bronchioles. The 
terminal divisions of the bronchioles open into the gas exchange 
unit, the alveoli. 
 
Tracheo – bronchial Tree: 
 
 The trachea is a tubular structure about 10 cm long and 1.5 
cm in diameter. It begins at the lower border of the larynx and 
entering the thorax, it divides into two branches-the right & left 
bronchi and each bronchus enters the corresponding lung at the 
hilum. The lumen of the trachea is kept patent by a number of       
C-shaped rings of cartilage which are deficient posteriorly. The 
gaps in the posterior wall are bridged by fibroelastic tissue and 
smooth muscle. The mucous membrane of the trachea is lined by 
ciliated columnar epithelium.  
 
The Lungs: 
 
 The lungs, one on either side, are large cone shaped spongy 
structures which occupy most of the thoracic cavity. 
 
They are comparatively light because of their content of air 
(right, approximately 600 g; left 550 g in a healthy adult). 
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 The lungs contain a high proportion of elastic tissue. This 
elasticity is responsible for most of the expiratory force in quiet 
respiration. Each lung lies free in its own pleural cairty attached 
only to the mediastinum by its root. 
 
The substance of the lung is formed by the numerous 
branches of the respiratory tract which form the bronchial tree, and 
several million airspaces which form the bulk of the lung; vascular, 
lymphatic, nervous and connective tissue form a smaller portion. 
 
Lobes of lungs: 
 
 The left lung is divided into two lobes by deep oblique 
fissures. It extends into the lung almost to the hilus, and separates 
the inferior and superior lobes. The superior lobe forms the apex 
and anterior margin of the lung. The inferior lobe makes up the 
diaphragmatic and the greater part of the posterior surfaces.  
 
 The right lung is divided by a similar oblique fissure.  This 
separates the superior and middle lobes from the inferior lobe. A 
second horizontal fissure extends from the anterior margin 
horizontally backwards to meet the oblique fissure in the mid 
axillary line. This fissure separates the wedge - shaped middle 
lobe from the superior lobe.  
 
Bronchi and Bronchioles: 
 
 Each main bronchus after entering the lungs divides into 
secondary bronchi, three on right and two on left, giving to each 
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lobe of the lung. Each secondary bronchus or lobar bronchus 
divides into segmental bronchi supplying a bronchopulmonary 
segment of which there are ten in the right & eight in the left lung.  
 
 The segmental or tertiary bronchi further divide several 
times, with progressive reduction in the length and diameter, giving 
rise to bronchioles with a diameter of 1 mm or less. The 
bronchioles branch further, the smallest subdivision being the 
terminal bronchiole with a diameter of about 0.5 mm. It has been 
estimated that the number of divisions from the tracheal bifurcation 
to the terminal bronchiole is 16. As branching occurs with a 
reduction in the diameter of each succeeding division. The total 
cross sectional area increases enormously from 2.5 cm2 in the 
trachea to over 10,000 cm2 at the end of the alveolar ducts. The 
bronchial tree upto including the terminal bronchiole is purely a 
conducting pathway for the passage of air. Respiratory gas 
exchange does not occur in this region and this portion is referred 
to as the ‘anatomical dead space’.  
 
Gas exchange apparatus: 
 
 The terminal bronchiole divides into the respiratory 
bronchiole. The respiratory brochioles gives rise to a number of 
short passages called the alveolar ducts. These open into wider 
alveolar sacs, on the walls of which are located the pulmonary 
alveoli. Some alveoli are present in respiratory bronchioles, but 
alveolar ducts are fully lined by alveoli. 
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BRONCHIAL SMOOTH MUSCLES: 
 
 The bronchial smooth muscles are present in the 
submucosal coat, appears in histological section as two helical 
tracts which run in opposite direction along the bronchial tree. They 
are innervated by the vagus and sympathetic nerves. Stimulation 
of the vagus causes contraction of the bronchial muscles resulting 
in broncho constriction. Bronchodilatation results from stimulation 
of sympathetic nerves, which relax the smooth muscles  
 
Blood vessels: 
 
 The branches of the pulmonary artery distribute venous 
blood to the lungs. There is a branch of the pulmonary artery to 
each lobe, bronchopulmonary segment, and lobule of the lung. The 
terminal capillaries lie in the walls of the alveoli and respiratory 
bronchioles where gaseous exchange takes place between the 
blood and the air.  
 
 
Pulmonary function tests: 
 
 Pulmonary function tests are very useful for evaluation of 
lung functions in respiratory disorders. Being physiological tests, 
they can only indicate whether the disease process has caused an 
impairment of function; they may not be able to detect early stages 
of the disease in which function has not been appreciably reduced. 
They also cannot make a specific clinical diagnosis. But they give 
an objective assessment of the functional status of the respiratory 
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system, and indicate the nature and extent of functional 
disturbance in disorders associated with pulmonary impairment 
and disability. Serial measurements are useful in following the 
course of disease, evaluating therapy and determining prognosis.  
 
TEST FOR VENTILATOR CAPACITY: 
 
 The simplest tests of dynamic ventilatory function are tests of 
forced expiration. A spirometer is used for these tests, and the 
procedure is called spirometry. Nowadays, computerized 
spirometers are available which give a print out of the data, as well 
as the predicted values.  
 
PULMONARY VENTILATION AND LUNG VOLUMES: 
 
 Pulmonary ventilation is the process by which fresh air from 
atmospher is drawn into the lungs during inspiration on an 
approximately equal volume of air is expelled during the 
subsequent expiration. Being a dynamic process, it is best 
described as the rate of movement of volume of air. However, it is 
convenient to define at this stage the quantities of gas in the lungs 
at different levels of the respiratory act. These can be expressed in 
terms of lung volumes and lung capacities.  
 
LUNG VOLUMES: 
 
 There are four lung volumes which do not overlap with one 
another. 
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1. TIDAL VOLUME (TV): 
 
 It is the volume of air inspired or expired during one 
respiratory cycle. TV in adults is about 500 ml during quiet 
breathing. 
 
2. INSPIRATORY RESERVE VOLUME (IRV): 
 
 It is the maximum volume of air that can be inspired by a 
forced inspiration after a normal inspiration. It is about 1400 – 2200 
ml in males and 1000-1800 ml in females.  
 
3. EXPIRATORY RESERVE VOLUME (ERV): 
 
 It is the maximum volume of air that can be expired by a 
forced expiration after a normal expiration. It is about 1000- 1800 
ml in males and 600 – 1200 ml in females. 
 
4. RESIDUAL VOLUME (RV): 
 
 It is the volume of air that remains in the lungs at the end of 
maximal expiration. It is about 1100 ml in males and 1000 ml in 
females.  
 
LUNG CAPACITIES: 
 
 Four lung capacities are recognized and each includes two 
or more lung volume. 
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INSPIRATORY CAPACITY (IC): 
 
 It is the maximum volume of air that can be inspired by 
forced inspiration after a normal expiration. It is about 1800 – 2000 
ml in men and 1400 – 2200 ml in women.  
 
VITAL CAPACITY (VC): 
 
 It is the maximum volume of air that can be expelled by a 
forced expiration after a maximum inspiration. 
 
Functional Residual capacity (FRC): 
 
 It is the volume of air remaining in the lungs at the end of a 
normal expiration. The FRC is physiologically very important. If 
there were no FRC and the lungs were completely emptied during 
each respiratory cycle, the alveolar PO2 & PCO2 will vary widely 
during breathing and will interfere with diffusion of respiratory 
gases.   
 
Total lung capacity (TLC) 
 
 It is the volume of air contained in the lungs at the end of a 
maximal inspiration 
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BRONCHIAL ASTHMA 
 
 
Asthma is defined as a chronic inflammatory disorder of the 
airways, characterized by reversible airflow obstruction causing 
cough, wheeze, chest tighteness and shortness of breath. 
Inflammation of the bronchial wall involving eosinophils, mast cells 
and lymphocytes, together with the cytokine and inflammatory 
products of these cells, induces hyper-responsiveness of the 
bronchi so that they narrow more readily response to a wide range 
of stimuli. Narrowing of the airways is usually reversible, but in 
some patients with chronic asthma the bronchal wall inflammation 
may lead to irreversible obstruction of airflow. 
 
PREVALENCE AND ETIOLOGY: 
 
 Asthma is a very common disease with immense social 
impact. Bronchial Asthma occurs at all ages but predominantly in 
early life. About one half of cases develop before age 10, and 
another third occur before age 40. In childhood, there is a 2:1 male 
/ female preponderance, but the sex ratio equalizes by age 30. 
 
 From an etiologic standpoint, asthma is a heterogenous 
disease and genetic (atopic) and environmental factors, such as 
viruses, occupational exposures and allergens are the factors 
results & provokes asthma.  
 
 Atopy is the single largest risk factor for the development of 
asthma. Allergic asthma is often associated with a personal and / 
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or family history of allergic diseases such as rhinitis, urticaria and 
eczema, with positive wheal and flare skin reactions to intradermal 
injection of extracts of airborne antigens with increased levels of 
IgE in the serum. 
 
 A significant fraction of patients with asthma present with no 
personal or family history of allergy, with negative skin tests and 
with normal serum levels of IgE. 
 
 These patients are said to have idiosyncratic asthma or   
non- atopic asthma. 
 
PATHOGENESIS: 
 
 Asthma results from a state of persistent subacute 
inflammation of the airways. The physiologic and clinical features 
of asthma derive from interaction among the resident and 
infiltrating inflammatory cells of the airway surface epithelium, 
inflammatory mediators and cytokines. The cells thought to play 
important parts in the inflammatory response are mast cells, 
eosinophils, lymphocytes and airway epithelial cells. The roles of 
neutrophils. Macrophages and other cellular constituents of the 
airways are less well defined. 
 
Pathphysiology: 
 
 The pathophysiologic hallmark of asthma is a reduction in 
airway diameter brought about of contraction of smooth muscle, 
vascular congestion, edema of the bronchial wall & thick, tenacious 
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secretions. The net result is an increase in airway resistance, a 
decrease in forced expiratory volumes and flow rates, 
hyperinflation of the lungs & thorax increased work of breathing, 
alterations in respiratory muscle function, changes in elastic recoil, 
abnormal distribution of both ventilation pulmonary blood flow & 
altered blood gas concentrations when patient presents for therapy 
the forced expiratory volume (FEV1)  or peak expiratory flow rate 
(PEFR) is typically & 40% of predicted. 
 
Hypoxia is a universal finding during acute exacerbations but 
frank ventilatory failure is relatively uncommon. Most individuals 
with asthma have hypocapnia and a respiratory alkalosis. The 
presence of metabolic acidosis in the setting of acute asthma 
signifies severe obstruction. Cyanosis is a very late sign. 
Therefore, in patients with suspected alveolar hypoventilation, 
arterial blood gas tension must be measured. 
 
Risk factors for asthma: 
 
1. Genetic susceptibility: 
 
 Asthma and atopy show clear indications of genetic 
susceptibility, the frequency of disease in family members is 
greater than in the population as a whole and is greater in identical 
than non – identical twins.  
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2. Allergen exposure: 
 
 Natural allergen exposure induces asthma and airway hyper-
responsiveness. Allergens & other substances liable to provoke 
attacks of asthma are pollens, mite’s in house dust, animal dander, 
etc. 
 
3. Environment and Air pollution: 
 
 Environmental causes of asthma are usually related to 
climatic conditions that promote the concentration of atmospheric 
pollution and antigens the air pollutants known to have this effect 
are ozone, nitrogendioxide and sulfur-dioxide. In these 
circumstances, although the general population can develop 
respiratory symptoms, patients with asthma and other respiratory 
diseases tend to be more severely affected. 
 
4. Occupational factors: 
 
 Occupation related asthma is a significant health problem, 
and acute and chronic airway obstruction have  been reported to 
follow exposure to a large number of compounds used in many 
types of industrial processes.  
 
 In general, the agents can be classified into high molecular 
weight compounds, which are believed to induce asthma through 
immunologic mechanisms and low molecular weight agents can 
release bronchoconstrictor substances  
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COMMON OCCUPATIONAL CAUSES OF ASTHMA 
 
High Molecular weight 
compounds 
Low Molecular weight 
compounds 
1.  Wood and vegetable 
 dusts 
 Eg. Those of Oak, grain 
 flour, castor bean, green 
 coffee bean, gum acacia & 
 tragacanth, etc. 
1.  Metal salts eg., platinum 
 chrome, nickel, vanadium, 
 etc.  
2.  Pharmaceutical agents –  
 e.g. antibiotics, piperazine, 
 etc. 
2.  Industrial chemicals & 
 plastics  
 Eg. Toluene diisocyanate, 
 ethylene diamine  
3.  Biologic enzymes  
 Eg., Laundry detergents, 
 pancreatic enzymes, 
 Bacillus subtilis, etc. 
 
3.  Formalin- Hospital 
 workers  
4.  Animal & insect dusts, 
 serum and secretions 
 laboratory animals, 
 prawns, oyster crab, bees, 
 etc. 
 
 
5.   Infections: 
 
 Respiratory infections are the most common of the stimuli 
that evoke acute exacebations of asthma. Viral infections can 
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actively and chronically destabilize asthma, and they are perhaps 
the only stimuli that can produce constant symptoms for weeks. 
The mechanism by which viruses induce exacerbations of asthma 
may be related to the production of T-cell derived cytokines that 
potentiate the infiltration of inflammatory cells into already 
susceptible airways. 85% of asthma attacks in children and 44% in 
adults were induced by upper respiratory tract infections, of which 
the great majorities were caused by rhinoviruses. 
 
6.  Exercise: 
 
 Exercise is a very common precipitant of acute episodes of 
asthma. Typically, the attacks follow exertion and do not occur 
during it. This stimulus differs from other naturally  occurring 
provocations, such as antigens, viral infections and air pollutants in 
that it does not evoke any long term sequelae.  
 
7.    Emotional stress: 
 
 Psychological factors can worsen or ameliorate asthma. 
Changes in airway caliber seem to be mediated through 
modification of vagal efferent activity. The extent to which 
psychological factors participate varies from patient to patient and 
in the same patient from episode to episode. 
 
 Patients with asthma can be categorized by whether their 
symptoms are intermittent or persistent, and by the severity of their 
symptoms & underlying airway narrowing tests. Even those with 
 37
mild asthma – intermittent or persistent can develop severe 
asthma. 
 
1. Mild intermittent asthma – symptoms occur less than weekly 
with normal or near normal lung function between episodes.  
2. Mild persistent asthma – symptoms occur more than weekly 
but less than daily with normal or near normal lung function 
between episodes.  
3. Moderate persistent asthma – symptoms occur daily with 
mild to moderate variable airflow limitation.  
4. Severe persistent asthma – symptoms occur daily and 
interfere with normal activities. There is frequent noctumal 
waking and moderate to severe variable airflow limitation.  
5. Severe asthma – severe distressing symptoms prevent 
sleep. Severe airflow limitation responds poorly to inhaled 
bronchodilators and can be life threatening  
 
Clinical Features: 
 
 The symptoms of asthma consist of a traid of dyspnoea, 
cough and wheezing. In its most typical form all three symptoms co 
exist. At the onset of an attack, patients experience a sense of 
constriction in the chest, often with a non-productive cough. 
Respiration becomes audibly harsh, wheezing in both phases of 
respiration becomes prominent, expiration becomes prolonged & 
patients frequently have tachypnoea, tachycardia and mild systolic 
hypertension. If the attack is severe or prolonged, there may be a 
loss of adventitial breath sounds, and wheezing becomes very high 
pitched. Further more the accessory muscles become visibly active 
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and a paradoxical pulse often develops. These two signs are 
extremely valuable in indicating the severity of the obstruction. 
 
 The end of an episode is frequently marked by a cough that 
produces thick, stringy mucus, which often takes the form of casts 
of distal airways (curschmann’s spirals) and, when examined 
miroscopically, often shows eosinophils and charcot-leyden 
crystals.  
 
Lung function tests: 
 
 Measurements of respiratory function may provide valuable 
information. First, in conjunction with the clinical assessment and 
to help establish a diagnosis. Secondly, they will help indicate the 
severity of the condition. Thirdly, serial measurements over time 
will show changes indicating disease progression or, alternatively, 
a favorable response to treatment.  
 
Forced expired volume in the first second: 
 
 The forced expired volume is defined as the volume expired 
in the first one second during forced vital capacity exhalation. This 
is measured from the analysis of the forced expiratory spirogram. 
In normal subjects, FEV1 is more than 80% of FVC values of FEV1 
are reduced in both central and peripheral airways obstruction. In 
patients with reduced lung volumes, FEV1 expressed as % FVC 
may be supranormal (>90%) 
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Peak expiratory flow rate (PEFR): 
 
 PEFR may be simply measured using equipment such as the 
Wright peak expiratory flow meter. The machines are cheap & 
portable and give the reading of the peak flow rate on a dial or a 
linear scale. This is defined as the maximum expiratory flow rate 
sustained for atleast 20 milliseconds during the forced expiratory 
manouvre.  
 
 Variability in PEFR of greater than 15-20% in a single day or 
from day to day is very suggestive of asthma. Most normal 
subjects demonstrate less than 10% variation in PEFR over a 24 h 
period. Similarly PEFR may be used as an index of response to 
treatment in asthma. Finally, PEFR is the most convenient 
measurement for use in the diagnosis of exercise induced asthma, 
where a fall in PEFR of greater than 15% following exercise is 
considered diagnostic.  
 
 Normal values are 400-600 L / min in young mean and 300 – 
400 L / min in young women.  Serial recordings of PEFR are useful 
in distinguishing patients with chronic asthma from those with fixed 
or irreversible airflow obstruction associated with COPD. 
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MATERIALS AND METHODS  
 
PROTOCOL 
 
AN OPEN CLINICAL TRIAL OF ILAVANGATHI CHOORNAM 
FOR THE TREATMENT OF IYA ERAIPPU (BRONCHIAL 
ASTHMA) 
 
 
 
1.  BACKGROUND 
 
      Eraippu noi has been classified into five types in Siddha 
system. Iya Eraippu is one among them. It correlates with the 
classical signs and symptoms of Bronchial asthma. 
            
In manuscripts, the etiology of the disease Iya Eraippu or 
Mandara Eraippu is stated as  
 
 
 
                  "ñ‰î£ó M¬óŠ¹ õO ñ¬ö °O˜ 
                   ªð£¼Àí¾ õ¼ W› è£ŸÁ 
                   õ‰î è£K¼ðQJ™ õO ïó‹H¡ 
                   õNòîQ™ ñ£ø£è„ ªê¡ 
                   Á‰î£¬õòˆ¬î ïQ ¶‡® 
                   òî¡ ªî£N¬ô Iè «õ£ƒè„ ªêŒ¶ 
                   º‰î£ù î¬ô ªî£‡¬ì JìºKf 
                   õ¼ˆîªôù ªñ£N‰îó¡«ø"      
 
Drug Ilavangathi choornam mentioned in Siddha literature 
Sigicha Rathna Deepam under Choorna Vilambam is indicated 
specifically for Eraippu Noi. The efficacy of this drug is not 
documented. Therefore, we propose to carry out an open clinical 
trial to estimate the efficacy of the drug.   
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1. AIMS 
 
     a) Primary aim 
 
To estimate the efficacy of Ilavangathi choornam in the 
treatment of Iya Eraippu. 
 
 
  b) Secondary aim 
 
To find out the side- effects of the drug, if any. 
 
3. POPULATION & SAMPLE     
                                                                                                                               
The population consists of patients with Iya Eraippu (Peak 
Expiratory Flow Rate > 200 L / minute) satisfying the inclusion & 
exclusion criteria mentioned below. The sample consists of Iya 
Eraippu patients attending the O.P.D of the Ayodthidoss Pandithar 
Hospital of the National Institute of Siddha, Tambaram Sanatorium, 
and Chennai-47. 
 
4. SAMPLE SIZE 
 
The trial size will be 50 patients. 
 
5. INCLUSION CRITERIA 
 
     1. Age 12 to 80 yrs. 
 
     2. Willing to be admitted in the Hospital for 30 days or willing 
to attend the O.P.D. once in 10 days.                                                
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6. EXCLUSION CRITERIA 
 
1. Smoking 
2. Alcohol consumption 
3. History of epilepsy or ischaemic heart disease 
4. Pregnancy  
5. Lactation. 
 
7. WITHDRAWAL CRITERIA 
 
      1.   Acute severe asthma 
      2.   Occurrence of any serious illness 
      
8. TRIAL DRUG AND DURATION 
         
        Drug – Ilavangathi choornam- 4 g t.d.s. with honey, after 
food. 
         
        Duration of trial treatment – 30 days 
 
10. TESTS AND ASSESSMENTS 
 
a. CLINICAL ASSESSMENTS 
 
1. Dyspnoea 
2. Cough 
3. Wheezing 
4. Sense of constriction of chest 
5. Type of breathing 
6. Accessory muscles of respiration 
7.   Hoarseness 
8.   Inability to sleep 
9.   Sputum production 
10. Trigger factors of asthmatic attack 
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11. Vocal resonance 
12. Vocal fremitus 
 
 
SIDDHA ASPECT- ENVAGAI THERVU 
 
1. Naa 
2. Niram 
3. Mozhi 
4. Vizhi 
5. Malam 
6. Moothiram-Neerkuri & Neikuri 
7. Meikuri (Sparisam) 
8. Naadi (Kaikuri) 
 
a) INVESTIGATIONS 
 
                   1. Blood test- TC, DC, ESR, Hb, RBC, Sugar (F/PP) 
                   2. Urine test – Albumin, Sugar & Deposits 
                   3. Motion test-Ova, Cyst. 
 
 
 
 
11. CONDUCT  
 
Iya Eraippu patients satisfying inclusion and exclusion 
criteria will be admitted to the trial. Informed consent will be 
obtained from the patients.  
 
Routine investigations will be carried out before and after the 
trial treatment. For   in-patients the trial drug will be administered 
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by the doctor. For out - patients the trial drug will be issued for 10 
days at a time. They will be advised to visit the O.P.D once in 10 
days. At each visit they will be clinically assessed.Also, they will be 
advised to bring back unconsumed drugs and return them during 
their subsequent visit.  
 
 
12. FORMS 
 
     Form I - Selection Proforma – It is used before admission 
of the patients to the trial. 
 
     Form II -Assessment Proforma- It is used once in 10 days 
during treatment. 
 
 
 
13. ANALYSIS 
 
 
The change in the PEFR before and after treatment will be 
analyzed using Paired t-test. 
 
           For the changes observed in the proportion of patients with 
signs / symptoms will be analyzed using Paired X² test. 
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RESULTS & OBSERVATION 
 
 Observations were made during the course of dissertation 
work with regard to the following features. 
 
1. Age & sex distribution  
2. Socio – economic status  
3. Occupational reference  
4. Personal habit & diet  
5. Past history & family history 
6. Distribution of thinai  
7. Kalam 
8. Paruvakalam 
9. Reference to mukutram 
10. Envagai thervu  
11. Neerkuri & Neikuri  
12. Recording PEFR (L/min), ESR (mm/hr), Eosinophil count             
13.    Signs & symptoms during admission into the trial         
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Table No.1 
 
Age – Sex Distribution of 50 Iya eraippu patients, 
NIS, Chennai – 47, 2007 
 
 
S.No. Age (yr) 
Sex 
Total 
Male Female 
1. 12-20 2 3 5 
2. 21-30 6 8 14 
3. 31-40 5 5 10 
4. 41-50 6 5 11 
5 51-60 4 2 6 
6. 61-70 2 1 3 
7. 71-80 1 0 1 
Total 26 24 50 
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OCCUPATIONAL REFERENCE 
PIE DIAGRAM NO. 1 
 
Housewife
34%
Miscellaneous
50%
Painter
4%
Farmer
8%
Carpenter
4%
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PAST HISTORY & FAMILY HISTORY 
 
BAR DIAGRAM NO.1 
 
 
50
24
8
0
5
10
15
20
25
30
35
40
45
50
Allergic Rhinitis Sinusitis Family history
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DISTRIBUTION OF THINAI  
 
PIE DIAGRAM NO.2 
Kurinji
8%
Neithal
76%
Marutham
16%
 50
 
 
PARUVAKALAM 
 
PIE DIAGRAM NO.3 
Munpanikaalam
80%
Pinpanikaalam
5%
Koothirkulam
15%
 51
 
 
MUKUTRAM  
 
PIE DIAGRAM NO.4 
Kapha
87%
Pitha
2%
Vatha
11%
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TABLE NO.2 
OBSERVATIONS IN 50 IYA ERAIPPU PATIENTS, NIS, CHENNAI – 47, 
2007. 
 
S. 
No. 
Date 
O.P. / 
I.P. No. 
Name 
Age /  
sex 
family 
h/o 
H  / o  
sinisutis 
/allergic 
PEFR 
Initial  
(L/min) 
final  
1. 20.11.2006 S8703 Rajeshkannan 14/M - - 270 360 
2. 20.11.2006 S8781 Mankali  49/M - - 440 450 
3. 20.11.2006 S8839 Mangai  30/F + + 280 400 
4. 22.11.2006 S9736 Durairaj 50/M - + 210 150 
5. 22.11.2006 S9671 Ramasamy 75/M - + 200 150 
6. 23.11.2006 S9994 Ragamathulla 32/M - - 400 390 
7. 23.11.2006 T114 Nesam  70/F - - 210 200 
8. 24.11.2006 T402 Mahalingam  59/M + + 150 180 
9. 27.11.2006 T1611 Anandakumar  20/M + - 330 440 
10. 28.11.2006 T2263 Aruldoss 31/M + + 400 480 
11. 28.11.2006 T2276 Ashok 28/M - + 300 350 
12. 29.11.2006 T2759 Prakash 25/M - - 320 350 
13. 29.11.2006 T2732  Poongodi 32/M - + 320 320 
14. 30.11.2006 T3084 Ranganayaki 57/M - + 320 350 
15. 02.12.2006 T3920 Paramasivam  42/M - + 210 170 
16. 03.12.2006 T4035 Balu 60/M - - 210 330 
17. 04.12.2006 T4409 Abarna  26/F - + 200 240 
18. 07.12.2006 T5941 Karthick 24/M - - 450 480 
19. 07.12.2006 T5864 Chellam 42/F + + 220 260 
20. 08.12.2006 T6183 Jayashree 40/F - + 250 370 
21. 12.12.2006 T8021 Hariharan 21/M - - 220 370 
22. 13.12.2006 T8443 Pushpa 40/F - - 300 360 
23. 15.12.2006 T9189 Chandika 43/F + + 250 260 
24. 20.12.2006 U1210 Bathuru 49/F + + 270 300 
25. 21.12.2006 U1683 Murali 32/M - - 290 380 
26. 21.12.2006 U1716 Karthikeyan 29/M + - 340 360 
27. 22.12.2006 U2075 Shanthi  43/F - - 300 360 
28. 23.12.2006 U2215 Dillibabu 34/M - - 400 470 
29. 25.12.2006 U3195 Anandhan  28/M + + 370 420 
30. 26.12.2006 U3373 Selvam  35/M + + 260 400 
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S. 
No. 
Date 
O.P. / 
I.P. No. 
Name 
Age /  
sex 
family 
h/o 
H  / o  
sinisutis 
/allergic 
PEFR 
Initial  
(L/min) 
final  
31. 28.12.2006 U4923 Selvi 32/F - - 250 250 
32. 29.12.2006 U5284 Cathirin 40/F - + 380 390 
33. 29.12.2006 U5154 Sathyaseelan 19/M - - 420 440 
34. 29.12.2006 U5066 Raja 42/M - - 220 260 
35. 30.12.2006 U5447 Parveen 25/F + - 250 330 
36. 02.01.2007 U6434 Sudha 54/F - + 250 350 
37. 03.01.2007 U6843 Suseela 47/F + + 280 150 
38. 03.012007 U6743 Janakiraman 60/M - - 280 260 
39. 04.01.2007 U7226 Alamelu 30/F + + 400 410 
40. 04.01.2007 U7196 Unnamalai 29/F - - 250 310 
41. 04.01.2007 542 Abdul Rehman  55/M + - 210 230 
42. 06.01.2007 U8035 Aishwarya 18/F + - 300 330 
43. 07.01.2007 U8328 Pushpalatha 21/F - - 200 420 
44. 07.01.2007 U8147 Parveen 26/F - + 290 290 
45. 07.01.2007 U8140 Muthukaruppan 50/M + + 210 100 
46. 10.01.2007 U9464 Selvam 65/M - - 320 360 
47. 11.01.2007 U040 Maniraj 68/M - - 200 230 
48. 18.01.2007 U1425 Raghunathan 47/M - - 250 310 
49. 19.01.2007 U1745 Shebagavalli 19/F + + 320 360 
50. 27.01.2007 U4859 Gomathy 22/F - - 250 280 
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TABLE NO.3 
 
RESULTS OF OBJECTIVE PARAMETERS BEFORE AND AFTER 
TREATMENT OF 50 IYA ERAIPPU TREATMENT, NIS, CHENNAI – 47, 
2007. 
Sl. No. Eosinophil count (%) ESR (mm / hr) 
 Before After Before After 
1. 8 6 12 12 
2. 2 3 12 8 
3. 2 2 20 12 
4. 4 3 20 12 
5. 5 4 4 4 
6. 2 2 7 4 
7. 2 3 8 7 
8. 4 4 24 20 
9. 6 5 22 22 
10. 6 5 8 12 
11. 6 5 16 8 
12. 8 10 16 6 
13. 4 5 8 8 
14. 4 2 12 22 
15. 2 2 8 10 
16. 8 10 8 10 
17. 10 10 12 16 
18. 2 2 12 16 
19. 2 8 4 6 
20. 6 6 16 12 
21 4 3 6 5 
22. 4 3 24 12 
23. 6 4 4 4 
24. 8 4 14 8 
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Sl. No. Eosinophil count (%) ESR (mm / hr) 
 Before After Before After 
25 4 3 12 10 
26. 4 3 14 6 
27. 4 3 58 24 
28 4 4 22 14 
29 4 4 28 20 
30. 6 3 14 8 
31. 12 6 12 16 
32. 8 2 28 22 
33. 6 4 24 18 
34. 4 4 22 25 
35. 6 4 12 8 
36. 4 4 16 12 
37. 4 4 12 10 
38 6 4 8 6 
39. 2 2 12 6 
40. 10 6 22 16 
41. 10 5 18 8 
42. 2 4 10 14 
43. 4 3 12 10 
44. 4 2 12 14 
45 4 3 12 8 
46. 10 6 8 12 
47. 8 6 20 16 
48. 3 2 12 8 
49. 4 4 16 12 
50. 2 2 12 10 
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THE T – TEST ON PAIRED OBSERVATIONS  
FOR OBJECTIVE PARAMETERS 
To make comparisons on the basis of paired observations on 
an individual e.g., before & after treatment, t - test is done. In such 
situations, the difference between the two observations must, on 
average, be zero, under the Null hypothesis; the t-test described 
above has therefore frequent practical application. Here, using t-
test the values of PEFR (L / min), ESR (mm / 1 hr), and Eosimophil 
count (%) are calculated for testing the significance. 
 
We could see the following data in Table No 4. 
 
The mean value of PEFR, before treatment in 50 Iya eraippu 
patients is 285.4 L/ min after treatment the mean value for the 
same is 328.4 L / min the difference in the means is 43. L / min. To 
test the significance of the difference paired t-test is done. The 
calculated paired‘t’ – test value is 4.559 L / min. In consequence, 
the quantity above is compared with P–value of 5% significance 
level. Hence, the null hypothesis is rejected, since the calculated 
value is greater then P < 0.05 (2.010) significance level. Therefore, 
the trial drug shows considerable improvement in patients which is 
statistically significant. 
 
The mean value of ESR, before & after treatment in 50 Iya 
eraippu patients is 14.9 (mm / hr) & 11.7 (mm / hr) respectively. 
The difference   in the means is 3.2 (mm / hr). To test the 
significance of the difference paired t-test is done. The calculated‘t’ 
value is 3.810 mm / hr. This quantity is compared with P value of 
5% significance level. Since, the calculated value is greater than 
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the P < 0.05 (2.010) significance level, Null hypothesis is rejected. 
Hence, the trial drug is considered statistically significant. 
 
The mean value of Eosmophil count, before and after 
treatment in 50 Iya eraippu patients included in clinical trial is 
5.06% and 4.14% respectively. The difference in the means is 
0.92%. The significance of the difference is calculated by paired t-
test. The calculated t-value is 3.159% compared with P < 0.05 
(2.010). Hence, the Null hypothesis is rejected. The trial drug is 
considered to be statistically significant. 
 
 
TABLE NO. 4  
 
RESULTS OF STATISTICAL ANALYSIS OF SOME OBJECTIVE 
PARAMETERS BEFORE AND AFTER TREATMENT OF 50 IYA ERAIPPU 
PATIENTS, NIS, CHENNAI – 47, 2007 
 
 
S.No. Parameter 
Mean 
Difference
Paired 
‘t’ test 
value 
P 
Value 
Significance 
of the 
difference 
Before 
treatment
After 
Treatment
1. 
PEFR (L / 
min) 
285.4 328.4 43 4.559 
< 
0.05 
2.010 
Statistically 
significant 
2. 
ESR – 1 
Hr (mm) 
14.9 11.7 3.2 3.810 
<0.05 
2.010 
Statistically 
significant 
3. 
Eosinophil 
(%) 
5.06 4.14 0.92 3.159 
<0.05 
2.010 
Statistically 
significant 
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TABLE NO. 5  
RESULTS OF SUBJECTIVE PARAMETERS BEFORE AND AFTER 
TREATMENT OF 50 IYA ERAIPPU PATIENTS, NIS, CHENNAI – 47 
 
S.No. Wheezing 
Constriction 
of chest 
Dyspnoea Cough 
 B A B A B A B A 
1. + − − − + − + − 
2 + − + − + + + + 
3. + − + − + + + + 
4. + − + − + _ + − 
5. + + + + + + _ − 
6. + + + _ + + + + 
7. + _ + + + _ + − 
8. + + + − + _ + + 
9. + − − − + + + + 
10. + − − − + _ + + 
11. + _ + − + _ + − 
12. + + _ − + + + + 
13. + − + − + + + + 
14. + − + − + + + − 
15. + − + − + + + − 
16. + + + + + + + + 
17. + + − − + + + + 
18. + − + − + _ + + 
19. + − + + + + + − 
20. + − + − + − + − 
21 + + + + + + + + 
22. + − + − + _ + − 
23. + − + − + _ + − 
24. − − + − + _ + − 
25. + − − − + _ + + 
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S.No. Wheezing 
Constriction 
of chest 
Dyspnoea Cough 
26. + + − − + + + + 
27. + + + + + + + + 
28. + − − − + + + − 
29. + − + − + + + − 
30 + − − − + _ + + 
31. + _ + − + + + + 
32. + _ _ − + − + + 
33. + _ + − + − + + 
34. + + _ − + + + + 
35. + − + − + − + + 
36. + − + + + − + − 
37. + − + − + − + − 
38. + − + + + + + + 
39. + − − − + _ + − 
40. + + + + + _ + − 
41. + _ + − + _ + − 
42. + + + − + + + − 
43. + − − − + − + − 
44. + + + + + + + + 
45. + − + + + + + + 
46. + − + + + + + + 
47. + − + _ + + + + 
48. + + + + + + + + 
49. + + − − + − + − 
50. + + + − + + + + 
 
Note:  B  -  Before treatment  
A  -  After treatment 
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THE CHI – SQUARE TEST FOR SUBJECTIVE PARAMETERS 
 
Data collected in the field of medicine is often qualitative 
here for e.g., the presence or absence of a symptom like cough, 
wheezing, dyspnoea and constriction of chest is taken. 
Comparisons between 2 or more proportions, and the test of 
significance employed for such purposes is called the chi-square 
test. 
 
The chi -square test is designed to examine whether a series 
of observed numbers in various categories of the data are 
consistent with the number expected in those categories on some 
specific hypothesis called Null hypothesis. By comparing the 
computed value with the tabulated value, the probability that the 
difference may have arisen from chance is obtained, this is called 
chi-square test. This test is very useful test of significance which is 
used here for symptoms like cough, wheezing, dyspnoca & 
constriction of chest in patients of Bronchial asthma.  
 
Observed data is represented in Table No. 6. 
 
In all, among 50 Iya eraippu patients before treatment cough 
is present as 86% & after treatment as 14%. The difference in 
treatment is 72% for the chi-square test, x2 value is calculated as 
15.05. On referring to tabulated values of the chi – square 
distribution with 1 degree, freedom, it is found that the probability 
corresponding to a chi – square value of 15.05 is greater than P < 
0.05 (3.84) level. Hence, reject the null hypothesis & say the cure 
is statistically significant. 
 61
 
In the 50 Iya eraippu patients underwent clinical trial with 
drug Ilavangathi choornam, wheezing was present 86% in before 
treatment and 14% in after treatment. The difference in treatment 
is 72%. x2 value is calculated as 28.03 On referring the  tabulated 
values of the chi-square distribution with 1 degrees of freedom it is 
found value of 28.03 is more than P < 0.05 (3.84) level. Hence, null 
hypothesis is rejected and the cure is statistically significant. 
 
The patient with dyspnoea before treatment is 76% and after 
treatment is 24%. The difference in the treatment is 52%. x2 value 
is calculated as 12.89. On referring to tabulated values of the chi – 
square distribution with 1 degrees of freedom it is found that the 
probability corresponding to x2 – value of 12.89 is greater than P < 
0.05 (3.84) level. Hence, Null hypothesis is rejected & the trial drug 
is proved to be efficacious.   
 
In all 50 Iya eraippu patients of asthma, the patient suffered 
with constriction of chest is 60% before treatment and 40% after 
the treatment. The difference is 20%. The x2 value is calculated, on 
referring to tabulated values of chi-square distribution with 1 
degrees of freedom. It is found that the probability corresponding 
to x2 value of 15.058 is greater than P < 0.05 (3.84) Hence, Null 
hypothesis is rejected & the trial drug shows statistically significant 
efficacy. 
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TABLE NO.6 
 
RESULTS OF STATISTICAL ANALYSIS OF SOME SUBJECTIVE 
PARAMETERS BEFORE AND AFTER TREATMENT OF 50                   
IYA ERAIPPU PATIENTS, NIS, CHENNAI – 47, 2007 
 
S.No. Parameter 
Percentage present 
Difference Paired x2 
P 
value 
Significance 
of the 
difference 
Before 
treatment 
After 
treatment 
1. Cough 86% 14% 72% 15.05 <0.05 
(1d.f) 
3.84 
Statistically 
significant 
2. Wheezing 86% 14% 72% 28.03 <0.05 
1 (d.f) 
3.84 
Statistically 
Sgnificant 
3. Dyspnoea 76% 24% 52% 12.89 <0.05 
1 (d.f) 
3.84 
Statistically 
significant 
4. Constriction 
of chest 
60% 40% 20% 15.058 <0.05 
1 (d.f) 
3.84 
Statistically 
significant 
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DISCUSSION 
 
 The present study brings on record, the work done on Iya 
Eraippu by clinical trial of Ilavangathi choornam with well defined 
protocol. 
 
 The present work was carried out on Iya Eraippu 
representing various views of its aetiology, classification, 
prodormal signs, signs & symptoms, Noi Naadal Noi mudal naadal, 
Naadinadai & also Dietary, Pranyamam & Yogasana prescriptions. 
 
 The Iya Eraippu patients are studied with regard to their past 
history of Ovammai & Peenisam, (allergic rhinitis, sinusitis & family 
history of asthma). This is represented by bar diagram (1) 
 
 In the Iya Eraippu patients admitted to clinical trial, age & sex 
distribution presented by Table No.1 & occupational history, 
distribution of thinai, incidence in paruvavakalam, derangement of 
mukuttram are studied and represented by pie diagram (1,2,3,4) 
respectively. 
 
 The observation on objective parameters like peak expiratory 
flow rate (PEFR) & laboratory investigation particularly, Eosinophil 
count and ESR (mm / hr) are calculated by statistical method and 
tested for significance. This is presented in Table No.4. 
 
 The observation on subjective parameters such as cough, 
wheezing, dyspnoea and constriction of chest are also analysed 
for statistical significance and presented in Table No.6. 
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 The preliminary biochemical analysis were carried out and 
presented.  
 
 The preliminary photochemical analysis were carried out with 
dichloromethane solvent and presented. 
 
 The acute toxicity study of drug Ilavangathi choornam is 
conducted on albino rats & recorded. 
 
 The trial drug is subjected to study on guinea pig for 
pharmacological activity – anti spasmodic effect & kymograph is 
recorded.  
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SUMMARY AND CONCLUSION 
 
 The open clinical trial of dry Ilavangathi choornam is 
conducted in 50 patients of Iya Eraippu at Ayothidoss Pandithar 
hospital of the National Institute of Siddha, Tambaram Sanatorium, 
Chennai - 47. 
 Among the fifty patients, the 50% of patients were having 
history of allergic rhinitis, 24% suffer from sinusitis & 4% with 
family history.  
 The patients were belonging to Neithal thinai are the most as 
to 76%. 
 The incidence of disease, Iya Eraippu looking with respect to 
paruvakalam showed about 80% suffer mostly during Munp 
anikaalam (December - Feburary).   
 
 The derangement of Kapha in Iya Eraippu patients is about 
87% vatha, 11% & pitha about 2% only. 
 
          In the 90% of the Iya eraippu patients neikuri is `muthu’ i.e. 
kabha neer. 
 
          The biochemical analysis of trial drug showed the presence 
of chloride. 
 
          The phytochemical analysis of the trial drug revealed the 
presence of carbohydrates & glycosides, phenolic compounds, 
tannins, phytosterols and essential oil. 
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         The pharmacological analysis of trial drug in guinea pig 
showed potent anti-spasmodic activity. 
 
         The trial drug is estimated non-toxic at a high dose of 2000 
mg/kg of body weight in albino rats. 
         This compound trial drug is formulated in such a way as to 
alleviate any digestive disturbances and also to prevent from any 
ill-effects due to excessive kaarpu suvai. 
 
          The trial drug had showed no adverse effects when given to 
the patient during the trial period. 
 
          The trial drug has been able to relieve cough and enhance 
expectoration, thereby relieving dyspnoea in Iya eraippu patients. 
 
          The objective parameters-PEFR (L/min), ESR (mm/hr), 
eosinophil count (%) all measured are proven statistically p<0.05 
significant. 
 
           The subjective parameters-cough, wheezing, dyspnoea, 
and constriction of chest showed significant improvement after the 
trial,proven statistically p<0.05. 
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PREPARATION OF TRIAL DRUG – ILAVANGATHI CHOORNAM 
 
The drug Ilavangathi Choornam is choosen for trial from the 
Siddha literature Sigicharathna deepam indicated for Iraippu noi. 
 
 The constituents of trial drug include- 
 
1. ,ytq;fk;  
2. ,ytq;fg;gl;il  
3. rjFg;ig  
4. fUQ;rPufk;   
5. Vyk;  
6. jdpah  
7. rPufk;  
8. jhsprgj;jphp  
9. rpWNjf;F  
10. jpg;gpyp %yk;  
11. nrt;tpak;  
12. rlhkhQ;rpy;   
13. [hjpf;fha;   
14. [hjpgj;jphp  
15. Xkk;  
16. Nfh\;lk;  
17. FNuhrhzp Xkk;  
18. tha;tpsq;fk;  
19. khrpf;fha;  
20. mf;fufhuk;  
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21. rKj;jpug;gok;  
22. rpWehfg;g+   
23. rpw;wuj;ij   
24. Rf;F  
25. kpsF  
26. jpg;gpyp  
27. nghd;KRl;il Nth; 
28. tpyhkpr;R Nth; 
29. kfug;g+  
Each of the above constituents are cleansed & purified, taken 
as same quantity then made into fine powder. The dosage is given 
as 4 gm three times a day (½ Njhyh ,UNtis) 
 
As per T.V. Sambasivapillai dictionary Vol.5 Page No.634 & 635 
kfug;g+ is known as nte;jak;. 
Also, by gr;rpiy - ghpghi\ mfuhjp Page 104 
& %ypif kUj;Jt mfuhjp Page 197 kfug;g+ is nte;jak;. 
 
Properties of trial drug: 
 
 The trial drug Ilavangathi choornam consists of 29 drugs. 
Most of its constitutents are having pungent taste (Kaarpu suvai). 
Least among them belongs to bitter and astringent taste (Kaippu & 
thuvarppu suvai). 
 
 We all know, that siddha system of medicine is based on five 
elements (Ik;g+jk;)  
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 A maruthuva thanipadal quotes the formation of six tastes 
 
from five elements. 
 
‘kz;ZlNd Gdy; jPf;fhy; Kiwahfr; Nrh;e;jpl;lhy; tUkh 
kpdpg;Gj; 
jpz;zkpyk; Jth;g;gpurk; rjhfjpNah lhh;jPtpd; jplkh 
Kiwg;Gk; 
vz;zwpa frg;G Kz;lhk; jz;zPhpy; jzypidg;ghy; vOkh 
Kth;g;G 
cz;zhpa mWRitapd; rpwg;gpnjDq; FUrpj;jh; ciuj;j 
kiwNa” 
 
kz;  +  ePh;    -       ,dpg;G(Sweet) 
   
kz;   +  jP     -   Gspg;G(Sour) 
 
kz;   +   fhw;W -  Jth;g;G(Astringent) 
 
ePh;   +   jP    -  cth;g;G(Salt) 
 
fhw;W + jP   - fhh;g;G(Pungent) 
 
fhw;W + ntsp  - ifg;G(Bitter) 
 
 
Maruthuva thanipaadal quotes the action & character of 
Kaarpu, Kaippu & Thuvarppu suvai as below. 
 
fhh;g;G Ritapd; nra;if : 
‘ew;grp a+f;fp... fhh;g;igr; rPh; 
J}f;fpaapy; Nthh;f;Fr; nrhy;” 
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   fhh;g;G - Fzk; : 
 
‘njhz;ilapy; Yz;lhk; kpz;L nra; gpzpfs; 
 mopj;jpLk; ehb ehs; milg;gpidf;fow;wpNa..” 
 
• The pungent taste stimulates appetite.  
• Cures the diseases of throat. 
• Destroys the vitiated kapha . 
 
   Jth;g;G Ritapd; ,ay;G : 
  
‘fl;LtJrw;Wf; fufug; ghf;FtJ 
jpl;lkha; Njhw;gjdQ; nra;tJ - kl;bw; 
nfhOg;GePh; ky;Fq; nfhOg;Gk; tul;ly; 
njhopyhe; Jth;g;Gr; Ritf;F” 
 
Astringent controls the excessive discharge of faeces, urine & 
bleeding. 
 
     nra;if: 
 
‘nghy;yh itak; khw;Wk;.. Fsph;e;j Jth;g;gpd; Ntiy” 
ifg;gpd; gz;Gk; nra;ifAk; 
 
It the astringent changes the decreased appetite due to various 
reasons. 
It changes the vitiated kapha. 
It controls the hyper secretions of glands in the body.  
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‘NtW fhuzk; tpisj;j t+z; ntWg; 
Nghl;L kpay;gh Naw;f tpUk;ghr; 
Ritahk; gpj;jika tpfw;gq;... 
tha;ePUwy; mow;rpAk; jzpf;Fk; 
nka;ePh;f; frpitAe; jbiaAe; jbAk; 
Cz;ryk; kyQ;ryk; epzryk; vd;gpDs; 
twl;Lk;....” 
 
The astringent taste changes the hatred towards food. 
It converts the vitiated pitha & Kapha. 
It controls the hypersecretions of glands in the body. 
 
Considering the actions & characters of Kaarpu, Kaippu & 
Thuvarpu suvai, the drug is formulated in such a way that the 
adverse effect of excessive kaarpu suvai is counteracted by 
Kaippu & thuvarpu suvai. Also, the kaarpu & thuvarpu suvai 
corrects the deranged deepakini in the body & produces good 
appetite. Both the kaarpu & thuvarpu suvai has the ability to control 
excessive secretion, as here, it will be appropriate to say the 
sputum production & expectorant. Hence Kaarpu suvai, by its 
inherent property antagonizes kapha by having fire as its 
component. 
Generally kapha disease patient’s complaints of reduced 
appetite or anorexia. In Iya eraippu patients their condition gets 
worse if they suffer from dyspnoea particularly after food due to 
improper digestion.Siddhars had given us plethora of drugs, mostly 
combination of herbs as compound drugs.The drug Ilavangathi 
choornam is also one among those formulation.Many drugs being 
the constituents of this choornam has the property of carminative, 
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stomachic, stimulant which suits the kapha noi patients gastric 
symptoms.They are- 
      Ilavangam,Ilavangapattai,Sathaguppai,Karunjeerakam, 
Elam, Dhaniya, Seeragam, Thalisapathri, Thippilimoolam, 
Jathikkai, Jathipathri, Omam, Koshtam, Vayvilangam, 
Sirunagapoo, Arathai, Chukku, Thippili,Vendayam. Ilavangam, 
Sathaguppai, Sadamanjil, Omam, Kurosanai Omam are having 
anti-spasmodic activity. Thalisapathri, Sadamanjil, Koshtam, 
Samudra pazham, Arathai, Milagu, Thippili, Ponmusuttai ver all 
have the expectorant property. 
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1. fpuhk;G / ,ytq;fk; - Cinnamomum zeylanicum  
 
Rit  :  fhuKk; tpWtpWg;GKs;sJ.  
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action :  Anti-spasmodic, Carminative, Stomachic.  
 
‘gpj;j kaf;fk; NgjpnahL the;jpAk;Nghk; 
Rj;jtpuj; jf;fLg;Ge; Njhd;WNkh - nkj;j 
,ytq;fq; nfhz;ltUf; Nfw;RfkhFk;. 
kykq;Nf fl;Lnkd tho;j;J”. 
m.F 
 
‘Rf;fpyel; lq;fh;z #h;tpaq;f yhQ;de;jhl; 
rpf;fy; tplhr; rh;th rpag;gpzpA - kf;fpf;Fl; 
lq;fg; g+NthL jhpglUe; Njhd;wpypy;  
tq;fg;g+ NthLiuj;J th” 
 
2.  ,ytq;fg;gil - Cinnamomum verum 
 
Rit  :  fhuKk; ,dpg;GKilaJ 
jd;ik  :   jl;gk; 
gphpT  :  ,dpg;G 
    Action:Stimulant, Carminative  
 
‘jhJ el;lk; Ngjp rUttp\k; Mfpa Neha; 
G+jfpu fQ;rpye;jpg; g+r;rptplQ; - rhjptplk;  
Ml;Lkpiug; NghbUky; Mfpa Neha;f; $l;lhw 
Xl;Lkpy tq;fj; Jhp” 
m.F 
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3. rjFg;ig - Anethum graveolens  
 
Rit  :  ,dpg;G fhh;g;G 
jd;ik  :   ntg;gk;  
gphpT  :  fhh;g;G 
Action: Antispasmodic, Stimulant,  Stomachic,  Carminative  
 
‘thjnkhL  #jpfhthjk;  rpuRNeha; 
NghJnrtp Neha; fgNeha; %Lfgk; - XJfpd;w 
%yf; fLg;G Kjph;gpdprk; NghFk; 
Qhyr; rjFg;ig ehL” 
m.F 
4. fUQ;rPufk; - Nigella sativa 
 
Rit  :  ifg;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action : Stomachic, Carminative, Emollient  
 
‘fUQ;rP ufj;jhd; fug;gndhL Gz;Zk; 
tUQ;rpuha;g; gPeprK khw;Wk; mUe;jpdhy;  
fha;r;ry; jiytypAq; fz;typAk; NghKyfpy;  
tha;r;r; kUe;njdNt it” 
m.F 
5. Vyk; - Elatteria cardamom 
 
Rit  :  fhh;g;G  
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
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Action: Stimulant, Carminative, Stomachic  
 
‘njhz;il tha;fTs; jhYF jq;fspy;  
Njhd;Wk; Nehajp rhuk;gd; Nkfj;jhy; 
cz;il Nghy; vOq; fl;b fphpr;ruk; 
coiy the;jp rpye;jp tp\Q;Ruk; 
gz;il ntf;if tpjhfNeha; fhrKk; 
ghOQ; Nrhkg; gpzptpe;J el;lKk; 
mz;il aPistd; gpj;jk; ,itf;nfy;yhk; 
My khq;fko; Vy kUe;jNj.” 
m.F 
6.  jdpah - Coriander Sativum  
 
Rit  :  fhh;g;G 
jd;ik   :  rPj ntg;gk; 
gphpT  :  fhh;g;G 
Action: Stomachic, Carminative, Stimulant  
 
‘nfhj;Jky;yp ntg;gk; Fsph;fha;r;ry; gpj;jke;jQ; 
rh;j;jptpf;fy; jhfnkhL jhJ el;lk; - fj;jpnaOk; 
thj tpfhh; klh; td;fh;j;j gptpuzk; 
g+jy;j;jpy; yhjfeWk; Nghw;W” 
m.F 
7. rPufk;  - Cuminum cyminum 
 
Rit  :  ,dpg;G 
jd;ik  :   jl;gk; 
gphpT  :  ,dpg;G 
Action: Carminative, Stimulant, Stomachic, Astringent  
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‘the;jp aUrp Fd;kk; tha;Neha;gP ypfkpiug; 
Ngw;wpUky; fy;yilg;gp yhq;rdKk;  - Nrh;e;jfk;ky; 
MrdF ghhpnaDk; me;jf; fpufzpAk; 
NghrdF lhhpAz;zg; Nghk;” 
m.F 
8. jhsprgj;jphp - Abies spectabilis  
 
Rit  :  fhh;g;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action : Expectorant, stomachic, carminative, tonic  
 
‘ehrp fsg;gpzpfs; ehl;gl;l - fhrQ;R 
thrk; mUrp tzkq;fhy; - tPrptU 
Nkfke;jk; mj;jprhuk; tpl;NlFe; jhspr;rj;jhy; 
MFQ; Rfg;gpurtk;” 
m.F 
9. rpWNjf;F - Clerodendron serratum  
 
Rit  :  ifg;G> Jth;g;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action : Stimulant  
 
‘fz;Lgh uq;fpnaDQ; rpWNjf; Fz;Nly; 
fhNyq;Nf gpj;jnkq;Nf fge;jh ndq;Nf 
njhz;L njhl;Lj; njhlh;Rthr fhr nkq;Nf 
Runkq;Nf ntwpnaq;Nf njhdpNeh naq;Nf” 
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m.F 
10. jpg;gpyp %yk;  -  Root of Piper longum 
 
Rit  :  fhh;g;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action : stomachic  
 
‘jhfgpj;jQ; Nrhfe; jzpahr; RukpUky; 
Nkfq; Fuw;fk;ky;  nka;f;fLg;Gk; - VFq;fhz;  
Jpg;gpyp% yq;fz;lj; jpg;gpypa jhk;eWf;Fj; 
jpg;gpypnad; NwnahUf;fhw; nrg;G.” 
m.F 
11. nrt;tpak; - Piper nigrum 
 
Rit  : fhh;g;G 
jd;ik : ntg;gk; 
gphpT  : fhh;g;G 
Action : Stomachic, Stimulant  
 
‘#iy mUrprd;dp njhy;ypUky; <isgpj;jk; 
Nkiyf; Fue;fk;ky; ntq;fypNeha; - %yRuk; 
ft;tpaq;fj; NjW fdjh tutplKQ;  
nrt;tpaq; nfhs;sptpLe; Njh;” 
m.F 
12.  rlhkhQ;rpy; - Nardostachys jatamansi 
 
Rit  :  fhh;g;G 
jd;ik  :   ntg;gk; 
gphpt  :  fhh;g;G 
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Action : Anti-spasmodic, Expectorant, Stimulant  
‘Fl;lQ; rpye;jptplk; Nfhu Guhz Ruk; 
cl;ldq;fhy; Ngjpfz;Nzha; Xl;bUky;  nrhl;buj;j 
gpj;jkpiug; NgFk; ngUq;Nfhiu vd;W iuf;FQ; 
Rj;jrlh khQ;rpiy nrhy;” 
m.F 
13. [hjpf;fha; - Myrstica fragrans  
 
Rit  :  Jth;g;G> fhh;g;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action :  Stimulant, Carminative,Tonic 
 
‘jhJ el;lk; Ngjp rUthrp aQ;rpuNeha; 
XJRth rq;fhrk; cl;fpufzp - NtNjh 
byf;fha; cUk;gpzpNghk; Vw;wkay; gpj;jq; 
Fyf;fh aUe;Jth;f;Ff; $W” 
m.F 
14.  [hjpgj;jphp - Myrstica fragrans  
 
Rit  :  Jth;g;G  
jd;ik  :  ntg;gk; 
gphpT  :  fhh;g;G 
Action : Stimulant, carminative, Hypnotic  
 
15. Xkk; - Trachyspermum ammi 
Rit  :  Jth;g;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
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Action : Anti-spasmodic, stomachic, Carminative,  
    Stimulant, Tonic 
 
‘rPjRuq; fhrQ; nrhpahke; jk;nghUky; 
Ngjpapiur; ry;fLg;G Nguhkk; - XjpUky; 
gy;nyhLgy; %yk; gfkpitNeh nad; nrANkh? 
nrhy;nyhLNghk; xknkdr; nrhy;” 
m.F 
16. Nfh\;lk; - Costus speciosus   
Rit  :  ifg;G> tpWtpWg;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action : Expectorant, Stimulant, Stomachic  
 
‘jpl;bfTs; mfLfsQ; nrd;dp ehtha; 
nrwpgpzpntg; gijg;Gjh th;j;jk; Cij 
Kl;bnaO Kistpuzk; Rthr fhrk; 
%bfj;Njh luTku tplq;fs;”    
Nj.F 
17. FNuhrhzp Xkk; - Hyocyamus niger 
Rit  :  fhh;g;G> rpWifg;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action : Anti – spasmodic  
 
‘ntF%j;jp jpuk;thjk; tphpael; lk;Gz; 
cFNgjp Al;fLg;gp NdhNl- kpFfug;ghd; 
jPuhf; fgkpitNghk; nra;aF Nuhrhdp nad;why; 
thuh kaf;fKW khy;”      
m.F 
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18. tha;tpsq;fk; - Embelia ribes  
 
Rit  :  ifg;G 
jd;ik  :  ntg;gk; 
gphpT  :  fhh;g;G 
Action : Stimulant, Stomachic, Carminative  
 
‘ghz;L - Fl;lk; Fd;kk; gUe;J}y; Neha; thje;  
jPz;L jphptplQ; rpue;Jz;lk; - g+z;lkb  
Neha; tpsq;ff; fhl;lhj Ez;fpUkp ahrdg;Gz; 
tha;tpsq;fq; fhl;l tpUkhh;”    
m.F 
19. khrpf;fha; - Quereus infectoria  
 
Rit  :  Jth;g;G 
jd;ik  :   jl;gk; 
gphpT  :  fhh;g;G 
Action : Astringent, Tonic  
 
‘mf;fuq;fs; Nghf;fptpLk; khwhj ntg;gfw;Wk; 
nka;f;FWjp khrpf;fha; nkd;NkYk; jf;fnjhU 
ghyh;fz Neha;Nghf;Fk; gd;Nkf Ke;njhiyf;Fk; 
Ntyida fz;zha; tpsk;G” 
m.F 
20. mf;fufhuk; - Anacyclus pyrethrum 
 
Rit  :  fhh;g;G 
jd;ik  :  ntg;gk; 
gphpT  : fhh;g;G 
Action  : Stimulant, Sialagogue  
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‘mf;fuhf; fhuQ; nra;A kltpJ jd;idf; Nfsha; 
  tpf;fYe; jbg;G khw;Wk; kplWfs; ghbtpf;Fq; 
 Rf;Fkh Nuhrpf fq;f sbet Njh\k; NghFk; 
  ,g;gb nfhs;t jw;F ,jKld; nrhd;d hPNj” 
 ‘mf;fpuh fhuj;ij Muwpag; Nghwhh;fhz; 
  cf;fpufh yj;Njh\ NkhLNk - jpf;F nkhop 
 nfhz;lhw;F ehj;jpUk;Gk; nfhk;gidNa! NfsPh; 
  fz;lhh;f;Fj; Njhlkpiy fhz;” 
m.F 
21. rKj;jpug; gok; - Barringtonia acutangula  
 
Rit  :  ifg;G 
jd;ik  :  ntg;gk; 
gphpT  : fhh;g;G 
 
Action : Expectorant  
 
22. rpWehfg;g+ - Mesua ferrea    
 
Rit  :   rpWifg;G> Jth;g;G 
jd;ik  :   jl;gk; 
gphpT  :  fhh;g;G 
Action : Astringent, Carminative  
 
‘rpWehfg; g+tpdJ nra;ifjidr; nrhy;Nthk; 
FwpahFk; Nkfj;ijf; nfhy;Yk; - newptpl;Lj; 
jPjha;r; nry;thaitAe; jPh;f;FkpU kw;Nghf;Fk; 
Nfhjha;‚ ,ijawpe;J nfhs;” 
m.F 
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23. rpw;wuj;ij - Alpinia officinalis  
 
Rit  :  fhh;g;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action : Expectorant, Stomachic  
 
‘njhz;ilapw;fl; Lq;fgj;ijj; J}uj; Juj;jptpLk; 
gz;ilr;rP jj;ijg; gwf;fbf;Fk;”.    
m.F. 
‘khh;ig alh;gpzpR thrfh rk;%yk; 
Nrhigjl;lr; #h;thj NrhzpjNeha; - jPgr; 
Ruj;ij aLg;Gh;gy; J}UWfz; Nehpd; 
muj;ij naLJfs jhk;”     Nj.F 
 
‘muj;ijapd; Fzj;ijNfsPh; mf;fuQ; 
 rd;dp Nghf;Fk; cuj;njhU ,Uky; khw;Wk; Xq;fpa cjpuk; Nghf;Fk; 
,iuj;jpLq; fhr nkl;Lk; tpQ;rpa $baKe;jPUk;  
Ruj;ijAk; ePf;F nkd;W nrhd;dJ Ntj E}Ny” 
   VL 
24. Rf;F - Zingiber officinale  
 
Rit  :  fhh;g;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action :  Stimulant, Stomachic, Carminative  
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‘#iyke;jk; neQ;nrhpg;G NjhlNkg; gk;koiy 
%yk; ,iug;gpUky; %f;FePh; - thyfg 
Njhlkjp rhuQ; njhlh;thj Fd;kePh;j; 
Njhlk; M kk;Nghf;FQ; Rf;F”    
m.F 
25. kpsF - Piper nigrum 
 
Rit  :  ifg;G> fhh;g;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action : Stimulant, Stomachic, Carminative  
 
‘rPjRuk; ghz;L rpNyj;kq; fpuhzpFd;kk; 
thjk; mUrpgpj;jk; kh%yk; - XJrd;dp 
ahrkg]; khuk; mld;Nkfk; - fhrkpit 
ehrq; fwpkpspfpdhy;      
m.F 
26. jpg;gpyp - Piper longum 
 
Rit  :  fhh;g;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action : Stimulant, Carminative, Expectorant  
 
‘<is apUk ypiug;Gg; grg;gpzpfs; 
khyp nthopahky; thl;LNk ahSKiw 
ghq;fh awpe;J nra;tPh; gz;bjj;ijg; gz;bjNu 
Ntq;if tha;g; ghd;fiz nka;”    
Nj.nt. 
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27. nghd;KRl;ilNth; - Sida acuta  
 
Rit  :  ifg;G 
jd;ik  :   ntg;gk; 
gphpT  :  fhh;g;G 
Action :  Expectorant, Stomachic, Tonic  
 
‘ thjnkhL gpj;jj;ij khw;WNk khepyj;jpw;  
rPj kfw;Wk; jpdtlf;Fk; - khNjNfs;! 
cz;bf;Fk; thridahk; Xq;fp typudiyf;  
fz;bf;Fk; nghd;KRl;il fhz;” 
m.F 
28. tpyhkpr;R Nth; - Plectanthrus vetiveroides  
Rit  :  ifg;G 
jd;ik  :   rPjk; 
gphpT  :  ,dpg;G 
Action : Anti – pitha  
 
‘ Nkfk; tpopnahpr;ry; tPwpuj;j gpj;jnkhU  
jhjfkj %h;r;irgpj;je; jd;kaf;fk; - NrhfQ;  
rpuNeha; ,itNaFQ; nra;atpyh kpr;Rf;  
nfhpRuKk; ,y;iy apir” 
m.F 
29. nte;jak; - Trigonella foenum graecum 
Rit  :  ifg;G 
jd;ik  :   jl;gk; 
gphpT  :  fhh;g;G 
Action :  Carminative, Astringent, Demulcent  
 
‘gpj;jTjp uk;NghFk; Nguhf; fzq;fSk;Nghk; 
mj;jpRue; jhfk; mfYq;fhz; - jj;Jkjp 
Ntf ,UknyhL tPW fak; jzpAk; 
NghfKWk; nte;jaj;ijg; Nghw;W.” 
m.F 
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QUALITATIVE PHYTOCHEMICAL ANALYSIS OF 
TRIAL DRUG ILLAVANGATHI CHOORNAM 
 
 The extract of the trial drug, Ilavangathi choornam in the 
dichloromethane solvent is subjected to chemical tests for 
identification of its active constitutents. 
 
1. Test for alkaloids  
 a) Mayer’s Reagent     - absent  
 b) Dragendorff’s Reagent    -        absent 
 
2. Test for Carbohydrates and glycosides  
 a) Benedict’s reagent    - Present  
 
3. Test for Proteins and amino acids  
 a) Ninhydrin Reagent                            -        absent 
  b) Biuret Reagent                                       -        absent 
 
4. Test for Phenolic Compounds and Tannins  
 a) Ferric Chloride Test         -        Present 
 
5. Test for Phytosterol  
 a) Libermann – Burchard’s Test        -       Present 
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6. Test for fixed oils and fats  
 a) Spot Test      -         absent 
 
7. Test for Saponins  
 a) Foam test      -        absent 
8. Test for gums and mucilages    -        absent 
 
9. Test for volatile oil     - present
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BIOCHEMICAL ANALYSIS 
 
 
 Tests for     Result 
 
Calcium  -  Absent     
Sulphate  -  Absent 
Chloride  -  Present  
Phosphate  -  Absent 
Carbonate   -  Absent 
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TOXICITY STUDY IN ANIMALS  
 
ACUTE TOXICITY STUDIES: 
In order to assess the safety of a drug various toxicity studies 
are carried out in animals under varying conditions of drug 
administration. The LD50 is determined trial drug using albino rats.  
Doses of the compound are given to 5 groups of albino rats each 
in a geometrical progression starting with a dose of 175 mg / kg 
and mortality in 24 hrs recorded.  
PROCEDURE: 
 ACUTE ORAL TOXICITY (24 hrs observation) up and down 
procedure (OECD 425) 
1. Animals - Albino rats (recommended species) 
2. Sex - Female (non pregnant) 
3. Group - Five groups 
4. Total number of animals used – 15 
5. Dose levels used : 
175 mg / kg  
520 mg / kg 
1000 mg / kg 
2000 mg / kg 
5000 mg / kg 
6. 
Sl.No. Dose level 
No. of animals 
exposed 
No. of animals 
showing toxicity 
1. 175 mg / kg  3 Nil 
2. 520 mg / kg  3 Nil 
3. 1000 mg / kg 3 Nil 
4. 2000 mg / kg 3 Nil 
5. 5000 mg / kg  3 2 (hyperactive) 
 89
7.   Body weight - 175 - 250 g 
8.  Time of dosing - 9.30 am on 8.03.2007 
 Time of toxic effect after dosing- 7.45 am on 9.03.2007 
9. No macroscopical changes observed in all groups 
10. Toxic effects - 175 mg / kg - Normal  
 After 4 hours 520 mg / kg - Normal with increased movement  
 After 4 hours 1000 mg / kg - Active, grooming behaviour  
 After 3 hours 200 mg / kg - Active, somersault acting, rearing 
action 
 5000 mg / kg - Hyperactive, aggressive increased fighting 
behaviour  
   After 6 hrs of dosing - moribund animals  
 
11. Caging conditions: 
  Animals are housed in polypropylene cages of 3 
animals / cage  
 
 i).   Bedding material  : Rice Husk  
 ii). Temperature  : 22 – 25oC 
 iii). Humidity            : 50% 
 iv). Photoperiod           :      12 hr light, 12 hr dark cycle  
 v). Diet              : Standard pellet diet  
     (Hindustan lever & co / Bangalore) 
              Water ad libitum 
12. Vehicle used for suspending test substance: corn oil  
13. Route: Oral  
14. Observation period: 24 hrs 
15. 2000 mg / kg is the LD50 and the dose fixed is 1/10 of LD50 -          
200 mg / kg  
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CONCENTRATION RESPONSE OF HISTAMINE AND 
MODIFICATION AFTER THE TEST DRUG 
 
AIM:  
 
 To record the concentration ~ response curve of histamine 
and its modification by an anti – histamine using guinea pig ileum 
preparation. 
 
PRINCIPLE: 
 
 Histamine is an antacid having profound physiological effect 
in the body besides the triple response caused by it, histamine has 
spasmogenic response on intestinal smooth muscle. By acting on 
H1 – histamine receptors it causes the concentration of intestinal 
smooth muscle. 
 
- Guinea pig  is highly sensitive to histamine  
- The Guinea pig ileum preparation is very commonly used for 
isolated tissue work. 
- Overnight animals are used to get better response on drugs 
on intestinal smooth muscles.  
 
REQUIREMENTS: 
 
Animal: Guinea pig (400 - 600 gm, overnight fasted) 
Drugs : Histamine stock solution (1 mg / ml) 
Physiological solution: Tyrode  
Test drug: Ilavangathi choornam (1 mg / ml) 
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PROCEDURE: 
 
- The Guinea pig is sacrificed by a blow on the head and 
carotid bleeding.  
- Cut open the abdomen and lift the caecum to trace the ileo 
caecal junction. 
- Cut and remove a few centimeter long of the ileal portion  
and immediately place it in the watch glass containing tyrode 
solution   
- Trim the mesentery and with gentle care clean the contents 
of the ileum by pushing the tyrode solution into the layers of 
the ileum. 
- Take on Piece of ileum of 2-3 cm long and tie the thread to 
top and the bottom and without closing the layers.  
- Tyrode solution maintained at 32-35oC and bubbled with 
oxygen or air. 
- A tension of 0.5 gm is applied and the tissue is allowed to 
calibrate for 30 minutes before adding drugs to organ bath. 
- Record concentration dependent response due to histamine 
using frontal writing lever.  
- Contact times of 30 sec and 5 min. time cycle are kept for 
proper recording of the response. 
- Record atleast four concentration dependent response due 
to histamine.  
- Add the trial drug to the reservoir containing tyrode solution 
and irrigate the tissue with antagonist containing tyrode for 
30 minutes. 
- Repeat the concentration response curve of histamine in the 
presence of trial drug. 
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- Label and fix the tracing and plot the graph as done in the 
experiment.  
 
RESULT: 
 
 Response of Histamine which contracts smooth muscle is 
decreased after the administration of test drug. Hence the given 
sample may have a smooth muscle dilating property.  
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PRANAYAMAM 
 
 The science of breath is called PRANAYAMAM it consist of 
Prana and Ayamam. Prana means life force or the vital energy. 
Ayamam means control i.e. control of breath. Life force is invisible, 
we cannot get hold of it. But, we know it is outward manifestation in 
the form of inspiration and expiration. 
 
 The gross manifestation of the life force of the physical body 
in the motion of the lungs. The first action of prana is expansion 
and contraction. So by breath we mean that the force which keeps 
the lungs active from the grosser to the subtle. The subtle force or 
energy is manifesting itself in the form of expansion is manifesting 
itself in the form of expansion and contraction.  
 
 If every atom is charged with prana, then by stimulating the 
vibratory conditions of that prana which are now going on in our 
system, we shall be able to stimulate all the atoms, which make up 
the molecules and cells of the body and make them vibrate on a 
higher plane and manifest more energy and more powers.  
 
 The act of breathing consists of three steps, namely 
a. The expulsion of the air from the lungs and 
 drawing in of fresh air from outside 
b. The retention of it in the lungs, to allow the 
exchange of gases that take place between the 
blood and the air breathed in. 
c. Then expulsion of air from the lungs. 
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The rechaka is biologically more important because it is an 
act of elimination, whereby the air spaces in the lungs are to be 
emptied of the foul air. To the extent that the retained air is thrown 
out by rechaka and only to that extent – can the fresh air enter the 
lungs by the next puraka, the breathing in. If the emptying is 
defective, some of the foul air is retained and to that extent less 
fresh air comes in. Hence the great importance of rechaka in 
practicing better breathing. If the emptying be made as thorough 
as possible, then more fresh air is drawn in and more oxygen is 
obtained by the next puraka, even though no effort is made to 
improve that part of breathing. So it is here recommended that, to 
begin with, the follower should confine his attention and efforts to 
the improvement of the rechaka and the kumbhaka. By this 
method alone, a considerable improvement in health will come in 
course of time. 
In the practice of breathing, the aim should be to increase 
the time taken for each breath, so that it should become more 
perfect and profitable. When this is done, there will be a reduction 
in the number of breathes taken in a single unit of time, but the 
breathing will become better and supply more oxygen to the blood, 
with less effort. Only after the rechaka becomes perfect, so that by 
that above, a considerable improvement of the whole constitution 
and of the the lungs is achieved. 
In the puraka, the air must be slowly and steadily drawn in, 
so that, first the diaphragm the floor fof the upper part of the trunk, 
should be pressed down; the breathing should not now be 
stopped, but must be continued, so that the chest expands 
sideways, the ribs rising up and allowing the top of the lungs to be 
filled with fresh air. In this latter process, the belly which has been 
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pushed outwards at first is drawn in again. This is deep breathing. 
When this is mastered, then it will be time to take up the 
improvement of the kumbhaka. 
 
While doing the pranayama, the individual should sit erect or 
stand erect.  Bed ridden patients, capable of doing pranayama can 
do it even on the bed, but to ensure correct posture they should be 
on a hard bed and not on a soft one. The dress worn at the waist 
should be kept slightly lose so that no pressure is felt on the 
ablomen. The dress, on the trunk of worn, should also be slightly 
loose to allow the lungs to expand & contract easily. 
 
The pranayama should be done either early in the morning 
or at dusk in the evening, when the stomach is empty. It should 
never be done when the stomach is loaded. A few rounds of 
pranayama say 10, 15, or 20, could be done each time.  
 
The mode of holding the fingers of the right hand for doing 
pranayama is explained. With the right thumb, the right nostril is 
gently closed and the individual should do the rechaka through the 
left nostril slowly, gently, without feeling any kind of strain, but to 
the fullest extent possible. When the rechaka is completed than 
then do puraka through the left nostril and gently & slowly as 
possible and do kumbhaka. Now rechaka done gently but to the 
fullest extent possible through right nostril. For doing rechaka and 
puraka the nostrils can be alternated. No exertion or force 
whatever is to be indulged in, for doing any one or more stages of 
this pranayama for a longer than what can conveniently done by 
the individual. 
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YOGASANAM 
 
 Yoga is the discipline leading to and the experience of 
reunion of the embodied individual soul (JIVATMA) with the 
universal soul (PARAMATMA) of which it is a partial expression.  
  
 For the patients of Iya Eraippu noi, few following yogasans 
are suggested to benefit their health. 
 
• VIBAREETHAKARANI 
• SARVANGASANAM 
• DHANURASANAM 
• ARTHA MATCHENDRASANAM 
• BHUJANGASANAM 
• MATCHASANAM 
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AN OPEN CLINICAL TRIAL OF ILAVANGATHI CHOORNAM FOR   
THE TREATMENT OF IYA ERAIPPU (BRONCHIAL ASTHMA) 
 
 
   FORMI -   SELECTION PROFORMA. 
 
1. OP/ IP NO :…………..     2 .Bed NO:………        3. S. NO:………… 
 
 
4. Name:…………………………………5 . Age(Yr) :……… 6.  Gender: M F 
 
 
7. Postal address:……………………………………………….. 
 
………………………………………………………………….. 
 
…………………………………Contact No………..…………. 
 
8. Complaints & Duration: 
 
 
 
 
 
 
 
 
9. History of present illness: 
 
 
 
 
 
 
 
 
 
 
10. Past history: 
 
 
 
 
 
 
 
 
11. Family history: 1. No  2. Yes. …………………………. 
 
 
12. Occupational history: Present: …………………………………. 
 
                                         Previous: ………………………………... 
 
 
 
       HABITS: 
            Yes   No 
 
13. Smoker       
 
14. Alcoholic     
 
15. Betel nut chewer 
 
16. Non - vegetarian                                  
  
 
 
 
      GENERAL EXAMINATION 
                                                                   
 
17. Body weight (Kg)   :  
 
18. Temperature (°F)       :      
 
19. Pulse rate / min   :  
  
20. Heart rate / min                  :   
 
21. Respiratory Rate / min       :     
 
22. Blood Pressure (mmHg)    :                                      /   /    
 
 
 
 
 
   
                                                                  Yes         No 
 
23. Pallor                                                 
 
24. Jaundice                                            
 
25. Clubbing                                         
 
26. Cyanosis                                         
 
27. Pedal Oedema                             
 
28. Lymphadenopathy                      
 
29. Jugular Venous Pulsation           
 
 
     SYSTEMIC EXAMINATION  
 
 
         A)  INSPECTION  
 
  30. Build:               1. Asthenic                  2.Normosthenic                3.Sthenic 
 
  31. Shape of the chest:  1. Normal                   2.Asymmetrical  
 
                                                                           
  32. Skin over the chest wall:                                             
 
                                    1. Normal                                       2. Engorged vein 
                                                            
                                                 
                            3. Discharging sinuses                          4. Intercostal scar 
  
  
                                                                        Present     Absent 
  33. Accessory muscles of inspiration 
     
  34. Dyspnoea on exertion 
     
  35. Dyspnoea at rest 
 
 
 
 
 
 
 
           B) PALPATION 
   
    36. Position of Trachea:        1.At midline                   2.Deviated  
 
    37. Vocal fremitus     1. Normal                       2. Increased                    3. Decreased 
 
    38.    AUSCULTATION 
                                                                                     
    1. Widespread polyphonic high pitched wheeze        
 
    2. Expiratory wheeze 
 
    3. Inspiratory &Expiratory wheeze 
 
    4. Inspiratory wheeze 
 
    5.  Normal vesicular breath sound 
 
 
 
         CLINICAL EXAMINATION 
                                                                Present     Absent    
    39. Dyspnoea  
 
    40. Non productive cough                                  
       
    41.  Wheezing  
 
                  1. Mild intermittent 
 
                  2. Mild persistent 
 
                  3. Moderate persistent 
 
                  4. Severe persistent   
         
 
                 Trigger Factors                                          
                                                             Yes            No 
      42. Cold air                       
 
      43. Tobacco smoke 
 
      44. Dust and fumes 
 
      45. Exercise 
 
      46. Viral infection 
 
      47. Drugs            
                                                        
      48. Emotion 
 
      49. Occupation 
 
                                                                       Present     Absent 
 
      50. Sense of constriction of chest 
     
      51. Accessory muscles of respiration 
 
              Sputum 
 
      52. Colour     1.  White               2.Green                 3.Yellow 
 
      53. Amount   1.Less                2.More 
 
      54. Consistency 1.Mucoid                2.Purulent                  3.Frothy  
         
 
      Peak Flow Meter 
 
55. PEFR (Peak expiratory flow rate) - 
 
 
 
           EXAMINATION OF VITAL ORGANS 
 
                                                                        Normal                   Abnormal 
 56. CVS                  :                                                                                                 
           
 57. RS                     :                                                                                                  
 
 58. Abdomen          :                                                                                                                                      
             
 
      SIDDHA ASPECTS 
 
59. NILAM: 
 
        1. Kurinji          2. Mulla           3.  Marutham          4. Neithal           5. Palai  
 
 
   60. KALA IYALBU: 
 
      1. Kaarkaalam           2. Koothirkaalam           3. Munpanikaalam 
  
      4. Pinpanikaalam         5. Ilavenirkaalam         6.Muduvenirkaalam 
 
   
 61. YAKKAI: 
 
         1. Vali           2.Azhal           3.Iyam            4. Vali azhal           5.Valiiyam 
  
         6. Azhalvali          7.Azhaliyam          8. Iyavali            9. Iyaazhal 
 
  62. GUNAM: 
 
          1. Sathuvam             2. Rasatham             3. Thamasam 
 
       PORI PULANGAL 
   
                                                                    Normal           Affected 
63. Mei                                                                                                                                                            
64. Vai                                                                                                                 
65. Kan                                                                                                              
66. Mooku                                                                                  
67. Sevi                                                                                       
 
 
   
          KANMENDHIRIUM / KANMAVIDAYAM 
   
                                                                    Normal  Affected 
68. Kai                                                                                                                                                            
69. Kaal                                                                                                                                                           
70. Vai                                                                                                                                                             
71. Eruvai   
72. Karuvai                                                                                                                                                      
 
 
UYIR THATHUKKAL 
 
          
         VALI 
            Normal  Affected 
73. Pranan 
74. Abanan 
75. Viyanan 
76. Uthanan 
77. Samanan 
78. Nagan 
79. Koorman 
80. Kirukaran  
81 Devathathan 
82 Dhananjeyan 
 
 
 
 
          AZHAL 
  Normal   Affected 
 
83. Analam 
84. Ranjagam 
85. Sathagam 
86. Alosagam 
87. Prasagam 
 
         IYAM 
 
  Normal  Affected 
88. Avalambagam 
   89. Kilethagam 
   90. Pothagam 
   91. Tharpagam 
   92. Santhigam 
 
      
 
         UDAL THATHUKKAL 
  Normal  Affected 
  93. Saaram 
  94. Senneer 
  95. Oon 
  96. Kozhuppu 
  97. Enbu                                                                                                                                    
  98. Moolai 
  99. Sukilam / Suronitham 
 
 
 
          ENVAGAI THERVUGAL 
  Normal  Affected 
100. Naa  
101. Niram 
102. Mozhi 
103. Vizhi 
104. Sparisam 
105. Naadi 
 
 
       Malam 
 
  Normal  Affected 
   106. Niram 
   107. Edai  
   108. Erugal 
   109. Elagal  
 
 
      MOOTHIRAM 
      Neerkuri 
  Normal  Affected 
110. Niram  
111. Manam 
112. Edai 
113. Nurai 
114. Enjal 
 
 
      Neikuri 
    
1. Aravam                                                          2.Moothiram 
                  
3. Muthu                                                            4.Aravil mothiram 
 
5. Aravil muthu                                                 6.Mothirathil muthu 
 
7. Mothirathil aravam                                        8.Muthil aravam 
 
9. Muthil mothiram                                           10.Asathiyam 
 
 
LAB INVESTIGATIONS 
 
        BLOOD 
 
115. TC (Cells / Cu.mm) 
 
DC (%)   116.N-              117. L-              118.  M-             119. E-               120.B-                  
 
ESR (mm) 121.½ hr-                          122.1 hr-             
 
123. Hb (gm %) -                       
 
124. Total RBC Count (million cells/cu.mm) -   
 
 
       Blood sugar (mg %) 
 
125. Fasting                           126. Post prandial                            127. Random 
 
 
      URINE 
 
  Present  Absent 
128. Albumin 
 
129. Sugar 
     Deposit 
  Present             Absent 
130. Pus cells 
131. Epithelial cells 
132. RBC 
133. Casts / crystal 
 
       MOTION    
                                                                    Present           Absent 
 
 134. Ova                                                                                                    
 135. Cyst    
 136. Occult Blood                                                       
     
            INCLUSION CRITERIA                                                          Yes             No 
 137. Age 12 to 80 yrs.                                                           
 
 138. Willing to be admitted in the Hospital for  
      30 days or willing to attend the O.P.D.  
      once in 10 days.                                                
                      
  EXCLUSION CRITERIA                                                              Yes               No 
139.  Smoking,                                                                                    
140. Alcohol consumption.                                                                   
141. History of epilepsy or ischaemic heart disease.                             
142. Pregnancy                                                                                       
143. Lactation.                                                                                          
 
                    
 
    144. Admitted to trial:           1.   Yes         2. No 
 
    145. If yes, S.No:                  146.OP/IP   1. O.P:                  2. I.P: 
 
    147. Drugs Issued for O.P Patients (Dosage in gm): 
 
    148. Date: 
 
    149. Station ………………   
 
  
 
    Signature of Doctor  
 
 
      NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
 
AN OPEN CLINICAL TRIAL OF ILAVANGATHI CHOORNAM FOR THE                
TREATMENT OF IYA ERAIPPU (BRONCHIAL ASTHMA) 
 
FORM – II ASSESSMENT FORM 
 
      1.   OP/IP.NO:________ 2.Bed NO: ___________     3. S.NO:______ 
 
4.    NAME: ___________________5.AGE (Yr): ______ 6. GENDER M                 F 
 
7. DATE OF ADMISSION: 
 
8. DATE OF ASSESSMENT: 
 
      9. NO: OF ASSESSMENT:   
 
 
 
              CLINICAL ASSESSMENT:    
                                                                   Present      Absent 
                                                 
      10. Dyspnoea                                       
 
11. Non productive cough                                  
         
 
 
 
       12.  Wheezing  
                  1. Mild intermittent 
 
                  2. Mild persistent 
 
                  3. Moderate persistent 
 
                  4. Severe persistent   
         
 
 
 
 
 
 
11 21 31
-2- 
 
             Trigger Factors                                          
                                                             Yes              No 
       13. Cold air                       
 
       14. Tobacco smoke 
 
       15. Dust and fumes 
 
       16. Exercise 
 
       17. Viral infection 
 
       18. Drugs      
                                                        
       19. Emotion 
 
       20. Occupation 
 
                                                                       Present     Absent 
 
       21. Sense of constriction of chest 
     
       22. Accessory muscles of respiration 
 
              Sputum 
 
       23. Colour: 1.White               2.Green              3.Yellow 
 
       24. Amount: 1.Less                2.More 
 
       25. Consistency: 1.Mucoid                2.Purulent               3.Frothy 
 
      Peak Flow Meter 
 
        26. PEFR (Peak expiratory flow rate) -   
 
           SYSTEMIC EXAMINATION  
 
 
            A)  INSPECTION  
 
       27. Build:     1. Asthenic                  2.Normosthenic                3.Sthenic 
 
       28. Shape of the chest 1. Normal                   2.Asymmetrical  
 
                                                                           
-3- 
 
 
 
  29. Skin over the chest wall.                                           
                                                                                                        
                                                1. Normal                           2. Engorged vein 
                                                            
                                                 
                            3. Discharging sinuses                          4. Intercostals scar 
 
  
  
                                                                         Present     Absent 
   30. Accessory muscles of inspiration 
     
   31. Dyspnoea on exertion 
     
   32. Dyspnoea at rest 
 
 
 
B)  PALPATION 
 
    33. Position of Trachea:    1. at midline                      2.deviated 
 
    34. Vocal fremitus:        1. Normal                     2. Increased                    3. Decreased 
 
 
     35.   AUSCULTATION 
                                                                                  
1. Widespread polyphonic high pitched wheeze        
 
2. Expiratory wheeze 
 
3. Inspiratory &Expiratory wheeze 
 
4. Inspiratory wheeze 
 
5. Normal vesicular breath sound 
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                                                               SIDDHA ASPECT 
 
         ENVAGAI THERVUGAL 
  Normal  Affected 
36.  Naa 
37.  Niram 
38.  Mozhi 
39.  Vizhi 
40.  Sparisam 
41.  Naadi 
 
     Malam 
 
  Normal  Affected 
   42. Niram 
   43. Edai  
   44. Erugal 
   45. Elagal 
 
     MOOTHIRAM 
     Neerkuri 
  Normal  Affected 
46. Niram  
47. Manam 
48. Edai 
49. Nurai 
50. Enjal 
 
51. Neikuri:  
 
1. Aravam                                                          2.Moothiram 
                  
3. Muthu                                                            4.Aravil mothiram 
 
5. Aravil muthu                                                 6.Mothirathil muthu 
 
7. Mothirathil aravam                                        8.Muthil aravam 
 
9. Muthil mothiram                                           10.Asathiyam 
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FOR O.P. PATIENTS: 
 
52. Drugs Returned 
 1. No. of gm: 
 
53. Drugs Issued: 
 2. No. of gm: 
 
 
LAB INVESTINGATIONS:  (at the end of 30Days) 
 
       BLOOD: 
 
 54. TC (Cells / Cu.mm) 
 
        DC (%)   55. N-              56.  L-               57.M-                58.E-                   59.B- 
 
 60. Total RBC Count (million cells/cu.mm)-     
  
        ESR (mm)   -    61.  ½ hr-              62.1 hr- 
 
 63.  Hb (gm %) -                       
 
 
     URINE 
 
  Present  Absent 
64. Albumin 
 
65. Sugar 
          
      Deposit 
                                                                    
                                Present             Absent 
66. Pus cells 
67. Epithelial cells 
68. RBC 
69. Casts / crystal 
 
 
70.  Date:  
 
71.  Station:……………………. 
         Signature of Doctor  
 
      NATIONAL INSTITUTE OF SIDDHA, CHENNAI – 47 
 
AN OPEN CLINICAL TRIAL OF ILAVANGATHI CHOORNAM FOR THE                
TREATMENT OF IYA ERAIPPU (BRONCHIAL ASTHMA) 
 
CONSENT FORM 
 
Certificate by investigator 
 
I certify that I have disclosed all details about the study in the terms readily understood 
by the patient. 
 
Date: ………….                                                                      Signature: ……………….. 
                                                                                        
          Name: …………………… 
 
Consent by Patient 
 
 
I have been informed to my satisfaction, by the attending physician, the purpose of the 
clinical trial, and the nature of drug treatment and follow-up including the laboratory 
investigations to be performed to monitor and safeguard my body functions. 
 
I am aware of my right to opt out of the trial during the course of the trial without having 
to give the reasons for doing so. 
 
I, exercising my free power of choice, hereby give my consent to be included as a subject 
in the clinical trial of Ilavangathi choornam for the management of Iya eraippu. 
 
 
 
 
 
 
Date: ……………                                                            Signature: …………………… 
                                                                                          Name: ……………………….. 
 
Date: …………….                                                            Signature of witness: …………. 
                                                                                           Name: ………………………… 
                                                                                           Relationship: ………………….       
.                  
 
 
